  
 
Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of [COMPANY_011] (or any of its 
affiliated companies). The use of such confidential information must be restricted to the recipi[INVESTIGATOR_21321], published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written 
consent of [COMPANY_011] (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other entit y which at the date 
of communication or afterwards (i) controls directly or indirectly [COMPANY_011], (ii) is directly or indirectly controlled by [CONTACT_13225],  with ‘control’ meaning 
direct or indirect ownership of more than 50% of the capi[INVESTIGATOR_13040], partnership or oth er entity 
According to template: RDSD-002540 VERSION N° 3.0 (19-FEB-2019) bas ed on TransCelerate CPT version 5  Page 1 
AMENDED CLINICAL TRIAL PROTOCOL 03  
Protocol title: A Randomized, D ouble-blind, Placebo-controlled, 
Parallel-group, 52-week Pi[INVESTIGATOR_208399], Safety, and Tolera bility of Dupi[INVESTIGATOR_208400]-to -severe Chronic Obstructive 
Pulmonary Disease (COPD) with Type 2 inflammation 
Protocol number: EFC15805 (NOTUS) 
Amendment number: 03  Compound number 
(INN/Trademark): SAR231893/REGN668 (dupi[INVESTIGATOR_12458]) 
 
Study phase: Phase 3 
Short title: Pi[INVESTIGATOR_208401], safety and 
tolerability of dupi[INVESTIGATOR_208402]-to-
severe COPD with Type 2 inflammation (NOTUS)  
Sponsor name: [CONTACT_13225]-Aventis Recherche & Développement 
Legal registered address: 1 avenue Pi[INVESTIGATOR_12954] 
[ZIP_CODE] Chilly-Mazarin FRANCE 
 
Monitoring Team’s 
Representative Name [CONTACT_9352] [CONTACT_208513](s): 
IND: [ADDRESS_248791]:  2018-001954-[ADDRESS_248792]:  [STUDY_ID_REMOVED] 
WHO: U1111-1211-8837 Other: Not applicable 
 
 
Approval Date: 28-Oct-2023 Total number of pages: [ADDRESS_248793]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 2 PROTOCOL AMENDMENT SUMMARY OF CHANGES  
DOCUMENT HISTORY  
 
Document Country/countries impacted 
by [CONTACT_208514], version 
Amended Clinical Trial Protocol [ADDRESS_248794]-2023, Version 1 (electronic 4.0) 
Amended Clinical Trial Protocol 02 All 16-Dec-2021, Version 1 (electronic 2.0) 
Amended Clinical Trial Protocol 01 All 29-Sep-2020, Version 1 (electronic 1.0) 
Original Protocol  06-Dec-2019, Version 1 (electronic 1.0) 
Amended protocol 03 (28-October-2023) 
This amended protocol 03 (amendme nt 3) is considered to be non substantial based on the criteria 
set forth in Article 10(a) of Di rective 2001/20/EC of the European  Parliament and the Council of 
the European Union. 
OVERALL RATIONALE FO R THE AMENDMENT  
The overall rationale for the changes implemented in  the protocol amendment is to add an interim 
analysis to determine if efficacy in the primary en dpoint of annualized rate of moderate or severe 
chronic obstructive pulmonary disease (COPD) ex acerbations is met at th e time of the interim 
analysis, as COPD is a disease with a high unm et medical need. The interim analysis will be 
performed when ≥92% of the information fraction for the pr imary endpoint is av ailable, but prior 
to all patients completing th e 52-week treatment period. 
 
Protocol amendment summary of changes table 
Section # and 
Name [CONTACT_82417] 1.1 Synopsis Added a bullet on an in terim analysis. Interim analysis is planned for 
efficacy as COPD is a disease 
with high unmet medical need. 
 Update of the data monitoring committee activities. Update 
Section 8.3.8 Disease-related events and/or disease-related outcomes not qualifying 
as AEs or SAEs Deletion of “and thus will not be considered unexpected 
condition” and “Any other AE not listed as an expected event in 
the IB or in this protocol  will be considered unexpected”. For accuracy and to clarify the current process. 
Section 9.[ADDRESS_248795]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 3 Section # and 
Name [CONTACT_82417] 9.4 Statistical 
Analyses Clarified the statistical analysis plan (SAP) will be finalized before the interim analysis.  Interim analysis is planned for efficacy. 
Section 9.4.1 Efficacy 
analysis Added details that if the primary endpoint is positive at the interim 
analysis, Week 52 endpoints will be analyzed using participants 
who had the opportunity to reach Week 52 at the time of the IA cut-off date. Interim analysis is planned for 
efficacy. 
 Update of the Statistical Analysis Methods wording for exploratory endpoints. Clarification 
Section [IP_ADDRESS] 
Multiplicity 
Considerations Added details on the Kim-DeMets spending function for the 
interim analysis and hierarchical procedure for multiple 
endpoints. Interim analysis is planned for 
efficacy. 
Section 9.5 Interim 
Analyses Updated text from “No interim analysis is planned” to add details of an interim analysis. Interim analysis is planned for efficacy. 
Section 10.1.4 
Committees structure Update of the data monitoring committee activities. Update 
Section 10.1.5 Dissemination of clinical study data Update of the web address for the clinical study data sharing “vivli.org”” replaces “c linicalstudydatarequest.com”. Update 
Throughout Minor editorial and document formatting revisions are made. Correction 
Amended Clinical Trial Protocol [ADDRESS_248796]-2023 
Version number: [ADDRESS_248797] OF FIGURES ............................................................................................................... ........................... 9  
1  PROTOCOL SUMMARY .............................................................................................................. . 10 
1.1  SYNOPSIS ...................................................................................................................... ............... 10  
1.2  SCHEMA ........................................................................................................................ ................ 15  
1.3  SCHEDULE OF ACTI VITIES (SOA) .............................................................................................. [ADDRESS_248798] anned treatm ent ....................................... 16  
1.3.2 Reduced schedule of events for patients after early treatment  discontinuation ............................ 20  
2  INTRODUCTION ............................................................................................................................ 22  
2.1  STUDY RATI ONALE................................................................................................................ ...... 22 
2.2  BACKGROUND .................................................................................................................... ......... 22 
2.2.1 Dupi[INVESTIGATOR_161376]-IL4R α monoclonal antibody .................................................................................. 24  
2.3  BENEFIT/RISK ASSESSMENT ..................................................................................................... [ADDRESS_248799]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 5 5.4  SCREEN FAILURES................................................................................................................ ...... 36 
6  STUDY INTERVENTION ............................................................................................................ ... 38 
6.1  STUDY INTERVENTION(S ) ADMINIST ERED .............................................................................. [ADDRESS_248800](s) .......................................................................................... .... [ADDRESS_248801](s) ......................................................................................  39 
6.2  PREPARATION/HANDLING/STORA GE/ACCOUNTABILITY ...................................................... 41  
6.3  MEASURES TO MINIMIZE BIAS: RA NDOMIZATION AND BLINDING ....................................... 42  
6.3.1 Methods of assigning patient s to treatment  group ......................................................................... 42  
6.3.2 Methods of blinding ........................................................................................................... ............. 43  
6.3.3 Randomization code brea king during t he study ............................................................................. 43  
6.4  STUDY INTERVENTION  COMPLIANCE ...................................................................................... 43  
6.5  CONCOMITANT THERAPY .......................................................................................................... 44 
6.6  DOSE MODIFI CATION ............................................................................................................. ..... 44 
6.7  INTERVENTION AFTER THE END OF THE STUDY ................................................................... 44  
7  DISCONTINUATION OF STUDY IN TERVENTION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL ........................................................................................... 45  
7.1  DISCONTINUATION OF STUDY  INTERVENTI ON  ..................................................................... 45  
7.1.1 Permanent disc ontinuation ..................................................................................................... ....... 45 
7.1.2 Temporary discontinuation of  study interv ention  .......................................................................... 47  
7.2  PARTICIPANT DISCONTINUATION/WIT HDRAWAL FROM THE STUDY .................................. [ADDRESS_248802] TO FO LLOW UP  ............................................................................................................. .... 48 
8  STUDY ASSESSMENTS AN D PROCEDUR ES ........................................................................... 49  
8.1  EFFICACY ASSESSM ENTS  ........................................................................................................ 49 
8.1.1 Disease-specific efficacy measures ............................................................................................ ... 49 
[IP_ADDRESS] Severity of COPD ex acerbations as defined by [CONTACT_81692] ......................................................... 49  
[IP_ADDRESS] Spi[INVESTIGATOR_208403] .................................................................................................................... .................. 50  
8.1.2 Clinical outcome assessments .................................................................................................. ..... 51 
[IP_ADDRESS] Patient reported outco me questionnaires ...................................................................................... 51 
[IP_ADDRESS] Other clinical outco me assessments ............................................................................................ . [ADDRESS_248803]-2023 
Version number: [ADDRESS_248804] ............................................................................................. ...... 55 
8.3.2 Time period and frequency for co llecting AE and SAE in formation ............................................... 56  
8.3.3 Method of detecti ng AEs and SAEs .............................................................................................. . 56 
8.3.4 Follow-up of AEs and SAEs ..................................................................................................... ...... 57 
8.3.5 Regulatory reporting re quirements for SAEs ................................................................................. 57  
8.3.6 Pregnancy ..................................................................................................................... ................. 57  
8.3.7 Adjudication Committee ........................................................................................................ ......... 57 
8.3.8 Disease-related events and/or disease-related outcomes not qualifying as AEs or SAEs ........... [ADDRESS_248805] complaints / medical device incidents (including 
malfunctions) ................................................................................................................. ................. 58  
8.4  TREATMENT OF OVERDOSE ...................................................................................................... 58  
8.5  PHARMACOKINETICS .............................................................................................................. .... 58 
8.5.1 Sampling time ................................................................................................................. ............... 58  
8.5.2 Handling proc edures ........................................................................................................... ........... 59  
8.5.3 Bioanalytic method ............................................................................................................ ............. 59  
8.6  PHARMACODY NAMICS .............................................................................................................. . 60 
8.6.1 Pharmacodynamic variables/biomarkers ....................................................................................... 60  
8.7  PHARMACOGE NOMICS  .............................................................................................................. . 61 
8.8  BIOMARKERS .................................................................................................................... ........... 61  
8.9  HEALTH CARE RESOUR CE UTILIZATION ................................................................................. 61  
9  STATISTICAL CONSIDERATIONS .............................................................................................. 62  
9.1  STATISTICAL HYPOTHESES ....................................................................................................... 62 
9.2  SAMPLE SIZE DETERMINATION ................................................................................................. 62  
9.3  POPULATIONS FO R ANALYSES ................................................................................................. 63  
9.4  STATISTICA L ANALYSES .......................................................................................................... .. 63 
9.4.1 Efficacy analyses  ............................................................................................................. .............. 64  
[IP_ADDRESS] Multiplicity cons iderations ................................................................................................... ........... [ADDRESS_248806]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 7 10  SUPPORTING DOCUMENTATION AND OP ERATIONAL CONSIDERATIONS ........................ 70  
10.1  APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS ....... 70  
10.1.1 Regulatory and Ethica l Considerations ......................................................................................... . 70 
10.1.2 Informed consent  process ...................................................................................................... ........ 70 
10.1.3 Data protection ............................................................................................................... ................ 71  
10.1.4 Committees structure .......................................................................................................... ........... 71  
[IP_ADDRESS] Data Monitoring Committee (DMC) ................................................................................................ 71  
[IP_ADDRESS] Adjudication committee ........................................................................................................ .......... 72 
10.1.5 Dissemination of clin ical study data .......................................................................................... ..... 72 
10.1.6 Data quality assurance ........................................................................................................ .......... 72 
10.1.7 Source documents .............................................................................................................. ........... 73  
10.1.8 Study and site  closure ........................................................................................................ ............ 73  
10.1.9 Publicatio n policy ............................................................................................................ ............... 74  
10.2  APPENDIX 2: CLINICAL L ABORATORY TESTS ......................................................................... 74  
10.3  APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLO W-UP, AND RE PORTING ................................................ 75  
10.4  APPENDIX 4: CONTRACEPTIVE GUIDANCE  AND COLLECTION OF PREGNANCY 
INFORMATION ................................................................................................................... ........... 80  
10.5  APPENDIX 5: GE NETICS .......................................................................................................... ... 82 
10.6  APPENDIX 6: LIVER AND OTHER SAFETY: SUGGESTED ACTIONS AND  FOLLOW-UP 
ASSESSMENTS  .................................................................................................................. ......... 83 
10.7  APPENDIX 7: LIST OF PROHIBITED LIVE ATTENUATED VACCINES ...................................... 85  
10.8  APPENDIX 8: COUNTRY-SPECIF IC REQUIREMENTS .............................................................. 85  
10.9  APPENDIX 9: ABBREVI ATIONS ................................................................................................... 8 5 
10.10 APPENDIX 10: ST. GEORGE’S R ESPI[INVESTIGATOR_208404] .......................................... 89  
10.11 APPENDIX 11: THE EXACT AS FORMATTED FOR PERSONAL DIGITAL ASSISTANT (PDA) ......................................................................................................................... .................... 95
 
10.12 APPENDIX 12: EXACT QU ESTIONNAIRE ................................................................................... 98  
10.13 APPENDIX 13: BODE ............................................................................................................. ..... 101 
10.14 APPENDIX 14:  EQ-5D-5L ........................................................................................................ ... 102 
10.15 APPENDIX 15: DEFINITION  OF ANAPHYLAXIS ....................................................................... 105  
10.16 APPENDIX 16: LIST OF OPPORTUNISTIC INFECTIONS ......................................................... 105  
10.17 APPENDIX 17: FUTURE USE OF SAM PLES ............................................................................. [ADDRESS_248807]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 8 10.18 APPENDIX 18: HIGH DOSE OF INHALE D CORTICOSTEROIDS: ADULTS ............................ 106  
10.19 APPENDIX 19: PROTOCOL AM ENDMENT HISTORY .............................................................. 107  
10.19.1 Amended protocol 01 (Amendment 01) (29-Septem ber-2020) ................................................... 107  
10.19.2 Amended protocol 02 (Amendment 02) (16-Decemb er-2021) .................................................... [ADDRESS_248808]-2023 
Version number: [ADDRESS_248809] OF TABLES  
Table 1 - Objectiv es and endpoints ............................................................................................ ................... 27  
Table 2 - Overview of study interventions administered ........................................................................ ....... 38 
Table 3 - Reliever medication - Salbut amol/Albuterol nebul izer solution ...................................................... 40 
Table 4 - Reliever medication - Levosalbutamol/Levalbuterol n ebulizer so lution ......................................... 40  
Table 5 - Reliever medication - Ipratropi[INVESTIGATOR_208405]/short-acting β agonists [SABA] nebulizer 
solutions ..................................................................................................................... ................................... [ADDRESS_248810]-2023 
Version number: [ADDRESS_248811] rictly confidential Page 10 1 PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Protocol title:  
A Randomized, Double-blind, Placebo-controlle d, Parallel-group, 52-week Pi[INVESTIGATOR_208406], Safety, and Tolerability of Dupi[INVESTIGATOR_208407]-to-severe 
Chronic Obstructive Pulmonary Diseas e (COPD) with Type 2 inflammation 
Short title:  
Pi[INVESTIGATOR_208401], safety and tolerability of dupi[INVESTIGATOR_208408]-to-severe COPD with Type 2 inflammation (NOTUS)  
Rationale: 
Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease worldwide, 
associated with significant economic burden, and for which available standard-of-care therapy 
shows insufficient treatment effect on symp toms, lung function, exacerbations and long-term 
evolution of the disease. Though th e inflammatory component in CO PD is typi[INVESTIGATOR_208409], there has been an  identified subgroup of COPD which is characterized by a 
concomitant elevation in blood eosinophils which suggests a Type [ADDRESS_248812] on lung function and 
symptom control will be evaluated over both the short and long term. 
Objectives and endpoints 
 
Objectives Endpoints 
Primary 
To evaluate the efficacy of dupi[INVESTIGATOR_12458] 300 mg 
q2w in patients with moderate or severe 
COPD as measured by 
 Annualized rate of acute moderate 
or severe COPD exacerbation 
(AECOPD).  Annualized rate of moderate* or se vere** COPD exacerbations over 
the 52-week treatment period compared to placebo. 
*Moderate exacerbations are recorded by [CONTACT_208515] 
(such as intramuscular, intravenous or oral) and/or antibiotics.  
**Severe exacerbations are reco rded by [CONTACT_208516][INVESTIGATOR_059], or observation 
for >24 hours in an emergency department/urgent care facility or 
resulting in death. 
For both moderate and severe events to be counted as separate events, they must be separated by [CONTACT_2669] [ADDRESS_248813]-2023 
Version number: [ADDRESS_248814] of dupi[INVESTIGATOR_12458] 300 mg 
q2w on 
 Pre-bronchodilator forced 
expi[INVESTIGATOR_3741] 1 second 
(FEV 1) over 12 weeks compared to 
placebo. 
 Health related quality of life, 
assessed by [CONTACT_63202] [ADDRESS_248815]. 
George’s Respi[INVESTIGATOR_6015] (SGRQ). 
 Pre-bronchodilator FEV
1 over 
52 weeks compared to placebo.  Change in pre-bronchodilator FEV 1 from baseline to Week 12 
compared to placebo. 
 Change from baseline to Week 52 in SGRQ total score compared to placebo. 
 Proportion of patients with SGRQ improvement ≥4 points at 
Week 52. 
 Change in pre-bronchodilator FEV
1 from baseline to Week 52 
compared to placebo.  
Overall design: 
Multinational, randomized, double-blind, placebo-cont rolled, parallel group (2 groups), 52-week, 
pi[INVESTIGATOR_9205] [ADDRESS_248816] (LABA), long acting muscarinic 
antagonist (LAMA) and/or inhaled corticosteroid  (ICS) background therapy (triple therapy unless 
ICS contraindicated). Study tr eatments are dupi[INVESTIGATOR_12458] [ADDRESS_248817] bo q2w administered 
during the 52-week randomized treatment period. The study includes 3 study periods. 
 Screening (4 weeks ±1 week). 
 Randomized investigational medicinal product (IMP) treatment period  
(52 weeks ±3 days). 
 Post IMP treatment period  (12 weeks ±5 days). 
Patients who satisfy the in clusion and exclusion crit eria will be randomized (1:1) to one of the 
following IMP treatment groups to be administered for 52 weeks. 
 Dupi[INVESTIGATOR_12458] 300 mg, administered as 1 subcutaneous (SC) injection q2w. 
 Placebo, administered as [ADDRESS_248818] ion of placebo matching dupi[INVESTIGATOR_12458]. 
Randomization will be stratified by [CONTACT_1606], ICS dos e (high dose ICS [yes/no]) at baseline, and 
smoking status at screening (curre nt smokers or not). Enrollment will be capped at 30% current 
smokers (as defined by [CONTACT_208517]). 
Treatment discontinuation follow-up: 
Patients who discontinue the study treatment pr ematurely (prior to completing the 52-week 
treatment period) will perform, as  soon as possible, the early treatment discontinuation (ETD) 
visit with all assessments normally planned for th e end of treatment (EOT) visit, to assure a 
complete clinical assessment in  close temporal proximity to th e premature termination of study 
treatment is available. In addi tion, to allow assessment of patie nt outcomes over the stipulated 
Amended Clinical Trial Protocol [ADDRESS_248819]-2023 
Version number: [ADDRESS_248820] rictly confidential Page 12 study period, patients will be asked and encouraged to complete all remaining study visits, and 
participate in all safety follow-up assessments acco rding to the visit schedule. For these patients 
the assessment schedule will be reduced (see Section  1.3.2) and visits during the planned 
treatment period may be conducted by [CONTACT_648] (except for planned EOT) if pa tient is unable to 
come in for a site visit. Asse ssments not completed via phone s hould be performed at the next 
scheduled visit. For further details please see Section 7.1.1. 
Post-IMP treatment follow-up 
Upon completing the 52-weeks randomized IMP treat ment period, patients will continue their 
background ICS/LABA/LAMA therapy and ente r the 12-week safety follow-up period. 
Adjustment of background medication is allowed at the discretion of the Investigator as clinically 
indicated during the post-treatment period (see Section  6.1.2 for further details). 
Disclosure Statement: This is a Parallel Treatment study with 2 arms that is blinded for patients 
and the Investigator. Number of participants: Approximately 924 patients are planned to be ra ndomly assigned to study intervention for an 
estimated total of 462 evaluable pa tients per intervention group (see Section  9.2). 
Intervention groups and duration: Study participation for each patient will be a total of approxi mately 69 weeks including up to 
5 weeks for screening, 52 weeks of IMP treatment period and 12 weeks of follow-up. Study intervention(s) 
Investigational medicinal products. 
 Dupi[INVESTIGATOR_12458] 300 mg. 
- Formulation: Dupi[INVESTIGATOR_12458] 300 mg for SC administration is supplied as 150 mg/mL 
solution in 2.25 mL prefilled glass syringes to deliver 300 mg in 2 mL. 
- Route of administration: subcutaneous injec tion. All IMP applications will be done as 
separate injections into different injection sites. 
- Dose regimen: dupi[INVESTIGATOR_12458] 300 mg q2w administered as 1 SC injection. 
 Matching Placebo for dupi[INVESTIGATOR_12458]. - Formulation: Placebo matching dupi[INVESTIGATOR_208410]. 
- Route of administration: subcutaneous injec tion. All IMP applications will be done as 
separate injections into different injection sites. 
- Dose regimen: Placebo administered as 1 SC  injection of placebo matching dupi[INVESTIGATOR_12458] 
300 mg (2 mL). 
Amended Clinical Trial Protocol [ADDRESS_248821]-2023 
Version number: [ADDRESS_248822] rictly confidential Page 13 Noninvestigational me dicinal products(s) 
Background therapy 
Patients should continue the regu lar administration of their previ ous standard of care background 
therapy for COPD throu ghout the study, including: 
Triple therapy: ICS + LABA + LAMA (Double therapy: LABA + LAMA allowed if ICS is 
contraindicated) 
 Formulation: dry powder inhaler (DPI), mete red dose inhaler (MDI) or pocket nebulizer. 
 Route(s) of administra tion: Oral inhalation. 
 Dose regimen: As prescribed. 
 Background medication should not be adjusted  during Screening. Patients are strongly 
encouraged to maintain their background therapy for the entire  duration of their treatment 
therapy. After 1 severe or 2 moderate ex acerbations of COPD, dose adjustments in 
background therapy, if required will be permitte d for symptom control and as needed for 
the remainder of the trial period. 
Reliever medication 
 Patients may use albuterol/salbutamol or levalbuterol/levosal butamol (including 
ipratropi[INVESTIGATOR_208411]/short acting β-agonist [SABA] combinations or terbutaline) as 
reliever medications as needed during the study. 
 Formulation: MDI, nebuliz er solutions or DPI. 
 Route of administratio n: oral inhalation. 
 Dose regimen: as prescribed. 
Statistical considerations: 
 Analysis populations 
- The efficacy population will be the intention- to-treat (ITT) population, defined as all 
randomized patients analyzed according to  the treatment group allocated by 
[CONTACT_17628]. 
- The safety population will include all patient s who actually received at least one dose 
or a partial dose of the IMP, analyzed acco rding to the treatmen t actually received. 
 Primary analysis: The annualized rate of moderate or  severe COPD exacerbation events 
will be analyzed using a negative binomial re gression model. The model will include the 
total number of events occu rring during the 52-week treatme nt period as the response 
variable, with the treatment group, region (pooled country), ICS dose (high dose ICS 
[yes/no]), smoking status at sc reening (current smokers or no t), baseline disease severity 
(as % predicted post-bronchodilator FEV 1), and number of modera te or severe COPD 
exacerbation events within one year prior to the study (≤ 2, 3, or ≥4) as covariates. 
Log-transformed observation duration will be used as offset variable. Patients who 
permanently discontinue the study treatment will be encouraged  to complete the study as 
planned and the additional off-treatment exacerbation events up to Week [ADDRESS_248823]-2023 
Version number: [ADDRESS_248824] rictly confidential Page 14 included in the primary analysis. Sensitivity  analyses for handling missing data may 
include pattern mixture model by [CONTACT_208518][INVESTIGATOR_208412]. 
 Analysis of key secondary endpoints:  
The change from baseline in pre-bronchodilator FEV [ADDRESS_248825] model with repeated measures  (MMRM). The model will include change 
from baseline in FEV 1 values up to Week 12 as respons e variables, and factors for 
treatment group, age, sex, baseline height, region (pooled country), ICS dose (high dose 
ICS dose [yes/no]), smoking status at scre ening (current smokers or not), visit, 
treatment-by-visit interaction, baseline pre-bronchodilator FEV 1, and FEV [ADDRESS_248826] except that the MMRM model will include the following covariates: treatment 
group, region (pooled country), ICS dose (hi gh dose ICS [yes/no]), smoking status at 
screening (current smokers or not), visit, treatment-by-visi t interaction, baseline SGRQ 
total score, and SGRQ baseline-by-visit interaction. The proportion of patients with SGRQ improvement ≥4 points at Week 52 will be 
analyzed using a logistic re gression model. The model will include treatment group, region 
(pooled country), ICS dose (high dose ICS [yes/ no]), smoking status at  screening (current 
smokers or not), and baseline SGRQ total scor e as covariates. Patient s with missing SGRQ 
total score at Week 52 will be considered as non-responders. 
 Multiplicity considerations:  Multiplicity is considered for testing multiple endpoints. 
The overall type-I error rate will be controlled  at the two-sided 0.05 level. Details will be 
provided in Section  [IP_ADDRESS]. 
 Safety analyses:  The safety variables,  including adverse events (AEs), laboratory 
parameters, vital signs, el ectrocardiography, and physical  examinations will be 
summarized using descriptive statistics. 
 An interim analysis will be performed during the study. See Section  9.5 for further details. 
Data Monitoring Committee: Yes 
 A data monitoring committee (DMC), independent from Sponsor, will be established for 
this study. This committee is comprised of exte rnally-based individuals with expertise in 
the diseases under study, biostatis tics, or clinical research. Th e primary responsibilities of 
the DMC are to review and evaluate the safety  and efficacy data during the course of the 
trial, review interim analysis results and make appropriate recomme ndations regarding the 
conduct of the clinical trial to the Sponsor. 
Amended Clinical Trial Protocol [ADDRESS_248827]-2023 
Version number: [ADDRESS_248828] rictly confidential Page 15 1.2 SCHEMA  
Figure 1 - Graphical study design  
 
1.3 SCHEDULE OF ACTIVITIES (SOA)  
The schedule of activities (SoA) for patients who co mplete the planned treatment is described in 
Section  1.3.1. Patients who withdraw from treatment prematurely mu st complete the ETD visit 
and follow the assessment in Section  1.3.[ADDRESS_248829]-2023 
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential Page 19 g Electronic diary is used for recording of patient’s answers to the EQ-5D-5L, EXACT and SGRQ questionnaires. This handheld devic e is dispensed at Screening Visit 1 (including instructions for use) and recorded 
information is reviewed on the other indicated days. At EOT visit the electronic diary is downloaded from the device and return ed to the site. 
h Complete physical examinations will include skin, nasal cavities, eyes, ears, respi[INVESTIGATOR_696], cardiovascular, gastrointestinal, ne urological, lymphatic, and musculoskeletal systems. 
i Vital signs, including systolic and diastolic blood pressure (mmH g), pulse rate (beats per minute), body temperature (°C), and respi[INVESTIGATOR_148235], baseline and every subsequent on-site 
visit. Height (cm) will be measured at screening (Visit 1) only. Body weight (kg) will be measured at screening (Visit 1) and a t EOT/EOS visits. 
j Hematology will include hemoglobin, hematocrit, platelet count, total white blood cell count, differential count, and total red blood cell count. Serum chemistry will include creatinine, blood urea nitrogen, glucose, 
lactate dehydrogenase, uric acid, total cholesterol, total protein, albumin, total bilirubin, alanine aminotransferase, asparta te aminotransferase, alkaline phosphatase, electrolytes (sodium, potassium, chloride), 
bicarbonate, and creatine phosphokinase. Urinalysis will include s pecific gravity, pH, glucose, ketones, blood, protein, nitrate, leukocyte esterase, urobilinogen and bilirubin. If any parameter on the dipstick is 
abnormal, a urine sample should be sent to the central laboratory for quantitative measurement. If positive for protein and/or red blood cells, microscopic analysis will be performed by [CONTACT_2237].  
Clinical laboratory testing at Screening Visit 1 will include hepatitis screen covering hepatitis B surface antigen (HBs Ag), h epatitis B surface antibody (HBs Ab), hepatitis B core antibody (HBc Ab), hepatitis C virus 
antibodies (HCV Ab), Human Immunodeficiency Virus (HIV) screen (Anti-HIV-1 and HIV-2 antibodies) and anti-nuclear antibody (ANA). In case of results showing HBs Ag (negative), and HBc Ab (positive), an HBV DNA testing will be performed prior to randomization to rule out a false positivity if the Investigator believes the patien t is a false positive, or to clarify the serological status if the Investigator finds it unclear to 
interpret in absence of known HBV infection. In case of results showing HCV Ab (positive), an HCV RNA testing may be performed to rule out a false positivity, if the Investigator believes the patient is a false 
positive. Note: Anti-ds DNA antibody will be tested if ANA is positive ( ≥1:160 titer).  
k Refer to central lab manual for collection details. 
l Only for women of childbearing potential. Pregnancy will lead to definitive treatment discontinuation in all cases. In case of positive urinary test, a serum pregnancy test should be performed as soon as possible to 
confirm the pregnancy. Pregnancy testing sh ould be done monthly, female  participants will be suppli ed with dipsticks for betwee n on-site visits. 
m Spi[INVESTIGATOR_208413] (ERS)/American Thoracic Society (ATS) [ADDRESS_248830] dose of salbutamol/albut erol or levosalbutamol/levalbuterol for at least [ADDRESS_248831] 12 hours (ultra-long acting LABA like vilanterol should be withheld for at least 24 hours) and withholding the last dose of LAMA for at least 24 hours. This will be verified before performing the measurements. Note: When both pre- and post-bronchodilator spi[INVESTIGATOR_208414], the post-bronchodilator spi[INVESTIGATOR_208415] (ie, 30 minutes for albuterol or other SABA). See Section  [IP_ADDRESS] for details. 
n Following randomization and during the treatment period - if spi[INVESTIGATOR_208416]-site visit for all visits prior to Week 12. If not performed at 
Week [ADDRESS_248832]-2023 
Version number: [ADDRESS_248833]. It is a 
fully human monoclonal antibody (mAB) directed against the interleukin 4 receptor alpha 
(IL-4Rα) subunit, a component of IL-4  receptors Type I and Type II, which mediate signaling by 
[CONTACT_8668]-4 (both receptors) and by [CONTACT_8668]-13 (Type II receptor). The IL-4R alpha receptor is present on 
multiple cell types known to be involved in the T ype 2 inflammatory process. Dupi[INVESTIGATOR_208417] a potential novel treatment for COPD  in those patients with evidence of Type 2 
inflammation as identified by [CONTACT_208519]. 
2.1 STUDY RATIONALE  
Chronic obstructive pulmonary dise ase (COPD) is a highly prevalent disease, associated with 
significant economic burden, and fo r which available standard-of-car e therapi[INVESTIGATOR_208418], lung function, ex acerbations and long-term progression of the 
disease. This study is designed to investigate th e efficacy and safety profile of dupi[INVESTIGATOR_208419]. The presence of a place bo arm is appropriate for the obj ectives of this  study, since it 
will provide the most robust assessment of the ef ficacy and safety of dupi[INVESTIGATOR_12458]. All patients will 
receive standard of care background medica tion throughout the study. The proposed study design 
provides the opportunity to inve stigate the efficacy of dupi[INVESTIGATOR_208420], prevention of moderate and severe exacerbations and symptom control. 
The effect on lung function and symptom control will be evaluated over short term and long term. 
2.2 BACKGROUND  
Chronic obstructive pulmonary dise ase (COPD) is a common, heterogeneous disease associated 
with an abnormal inflammatory immune response  of the lung to noxious particles and gases (1 ). 
It results in progressive airflow obstruction that is mainly irreversible or only partially reversible 
and in many cases loss of alveolar tissue and em physema. The disease typi [INVESTIGATOR_208421], where the chronic inflammation causes structural changes including narrowing of the 
small airways, and destruction of the lung pa renchyma that leads to the loss of alveolar 
attachments to the small airway s and decreases lung elastic recoil. The inflammation component 
of COPD is thought to involve  many cell types including stru ctural cells, T lymphocytes, 
neutrophils, macrophages, and th eir biological products. Though th e inflammatory component in 
COPD is typi[INVESTIGATOR_208422], there has been an iden tified subgroup of COPD 
which is characterized by a concomitant elevation in blood eosinophils which suggests a Type [ADDRESS_248834] (including silica) and fumes. 
The most common clinical symp toms include chronic dyspnea, cough and/or sputum production. 
COPD exacerbations are important contributors to the disease bur den, particularly in severe 
COPD. Exacerbations are often triggered by [CONTACT_208520] a nd/or bacterial infecti ons, but tend to occur 
Amended Clinical Trial Protocol [ADDRESS_248835]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 23 also more frequently in patients with COPD with Type 2 inflamma tory signature, where they may 
be preceded by [CONTACT_208521]. Exacerbations may trigger a major inflammatory 
response followed by [CONTACT_208522][INVESTIGATOR_3741] 1 second (FEV1)  decline, more rapid disease progression and 
increased risk of mortality. 
In particular, current smokers with COPD have an accelerated decline in lung function, which is 
heterogeneous, exhibits considerable inte r- and intra-individual  variability and FEV 1 decline can 
reach more than 100 ml/year in some patients with COPD. Smoking cess ation attenuates the 
accelerated loss of lung function, but neither smoki ng cessation nor current th erapi[INVESTIGATOR_45732] a 
substantial recovery of lung function lo st at the time of smoking cessation ( 2). 
“Type 2 inflammation” exists acr oss a spectrum of diseases. This inflammatory cascade is 
regulated by T-helper Type 2 cells and is driven by [CONTACT_208523]-4, IL-5, and IL-13 cytokines. 
(3). Peripheral and airway eosinophils are presen t in asthmatics with Type 2 inflammation ( 4). 
Markers of Type [ADDRESS_248836] been identified in 
subgroups of patients with COPD and are linked to peripheral eosinophils ( 5, 6).  In addition, 
peripheral eosinophilia (>300), as a marker of Type [ADDRESS_248837] clinical features ( 6, 7) including more frequent 
respi[INVESTIGATOR_22315] (8) as well as worse overall mortal ity. At the same time, this group, 
similar to asthmatics with Type 2 inflammation ( 9), also appears to be mo re responsive to ICS ( 6). 
Additional biomarkers for Type  [ADDRESS_248838] be en less well studied in COPD. 
Dupi[INVESTIGATOR_208423]4Ra, leading to inhibi tion of the Type 2 cytokines IL-4 and IL-13. 
In addition, IL-13 has been shown to block mucus secretion. We hypothe size that blocking key 
mediators of Type 2 inflammation as well as re ducing mucus production in COPD will lead to a 
reduction in inflammatory exacerbations as well as an improvement in lung function. We will use 
peripheral eosinophilia to identify COPD  patients with Type 2 inflammation. 
Chronic obstructive pulmonary dise ase is a highly prevalent, se rious, and progressive disease 
resulting in significant morbidit y, mortality, and economic burden ( 10, 11). Based on the BOLD 
and other large scale epi[INVESTIGATOR_155960] l studies, it is estimated that the number of COPD cases in the 
world was 384 million in 2010, with a global preval ence of 11.7% (95% confidence interval: 
8.4%-15.0%) (10). In the US alone there are more th an [ADDRESS_248839] 
common cause of death. In Europe the number of  cases is estimated to  be  66.4 million in 2010 
among people aged 30 years or more, with a prevalen ce of 13.7% (13.5% - 13.9%) ( 10). 
Globally there are around [ADDRESS_248840]-2023 
Version number: [ADDRESS_248841] s (LAMA) and/or long-acting β2-agonists (LABA). As disease 
progresses, in particular in patients with frequent exacerbations, bronchodilators are combined 
with anti-inflammatory drugs such  as inhaled corticosteroids (I CS), and phosphodiesterase Type 4 
(PDE-4) inhibitors (roflumilast) ( 12, 13, 14). The major limitations of the existing agents for 
COPD include modest efficacy and for inhaled co rticosteroids an increased risk of respi[INVESTIGATOR_208424], in  particular at high doses of potent molecules and in patients 
with severe COPD. While inhaled co rticosteroids have a consistent effect in reducing the risk of 
moderate COPD exacerbations defined by a COPD deterioration requiring the use of systemic corticosteroids and/or antibiotics, there is no co nsistent benefit on severe exacerbations requiring 
hospi[INVESTIGATOR_602]. There is increasi ng evidence that this treatment effect is primarily driven by 
[CONTACT_208524]  2% blood eosinophils ( 15). 
Systemic, mostly oral corticosteroids are largely reserved for the treatmen t of exacerbations given 
their unacceptable safety profil e with heightened concerns fo r a COPD population. No approved 
therapeutic agent blocks  the decline in FEV
1 over time or modifies the progressive disease course 
of COPD. Thus there is a high unmet need for more effective treatment of this disease. 
Currently, no targeted biological treatments addressing the immunolog ical underpi[INVESTIGATOR_208425]. In Phase 3 trials, the anti- interleukin (IL-5) mAb mepolizumab showed a 
modest 18%-20% reduction of exacerbations in COPD patient s with high blood eosinophils (16 ). 
The anti-IL-[ADDRESS_248842] iven by [CONTACT_208525]. In this study, no reduction of exacerbations wa s seen in the per-protocol 
population, and a numerical, but not statistically significant, reducti on of exacerbation was seen in 
the subgroup of patients w ith high blood eosinophils ( 17). 
Thus, significant unmet medical needs continue to exist in the growing popul ation of patients with 
COPD. The main objective for new treatments is to further improve COPD symptoms, lung 
function, and prevent exacerbations, while optimizing adherence to the treatment. 
2.2.[ADDRESS_248843] identifie d IL-4 and IL-13 variants that occur more 
frequently in COPD patien ts than in controls ( 18), and Type 2 gene expression score has been 
identified in ~20% of COPD patients ( 19, 20). It is known that dupi[INVESTIGATOR_208426]. 
Eosinophilic airway inflammation is evid ent in 20%-40% of COPD patients ( 21, 7) with increased 
levels of eosinophils in blood, sputum, and bron chial biopsies reported during acute exacerbations 
(21, 12). Additionally, through dupi[INVESTIGATOR_12458]’s blockade of  the IL-[ADDRESS_248844]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 25 Dupi[INVESTIGATOR_208427]-4R α subunit blocks signaling of th e signature [CONTACT_39764] 2 cytokines 
(IL-4 and IL-13) has a broader impact on Type  [ADDRESS_248845] an 
improved potential to treat aspects of COPD  inflammation which are driven by [CONTACT_39764] 2 
inflammatory tone. 
Dupi[INVESTIGATOR_208428] r the treatment of atopic dermat itis (AD), asthma, and chronic 
rhinosinusitis with nasal polypos is (CRSwNP), and is in late stage development for eosinophilic 
esophagitis. At the time of prot ocol finalization, dupi[INVESTIGATOR_208429]. In  asthma, it has demonstrat ed satisfactory safety 
and excellent efficacy in a broad spectrum of as thma patients, including severe asthma patients 
and previous smokers. The planned Phase 3 prog ram including this study will provide evidence 
on the efficacy and safety of dupi[INVESTIGATOR_208430] 2 inflammation 
as reflected by [CONTACT_208526] ( ≥0.3 Giga/L) at screening. 
2.3 BENEFIT/RISK ASSESSMENT  
Dupi[INVESTIGATOR_12460]® (dupi[INVESTIGATOR_12458]) 150 mg/mL solution for injecti on is authorized for marketing in over  
40 countries worldwide including the [LOCATION_002]  (US), European Union (EU) (Centralized 
Procedure), and Japan for th e adult moderate-to-severe AD indication. The marketing 
authorization for treatment of  adult AD in the US was approved on 28 March 2017. The European 
Commission (EC) granted marketing authorizat ion for dupi[INVESTIGATOR_173756] 26 September 2017 for use 
in adults with moderate-to-severe AD who are candidates for systemic therapy. Dupi[INVESTIGATOR_208431] 11 March 2019 for use in adolescent patients ( ≥12 years) with 
inadequately controlled moderate-to-severe AD. It was also approved as an add-on maintenance 
treatment for CRSwNP in the US on 26 June 2019 and in the EU on 29 October 2019. Approval 
was received for dupi[INVESTIGATOR_208432] m the US Food and Drug Adminis tration (FDA) on 19 October 
2018 for use in adults and adolescents ( ≥12 years) with moderate-to-severe asthma. In the EU, the 
EC issued a positive decision on 07 May 2019 for use in adults and adolescents (≥ 12 years) with 
severe asthma with type 2 inflammation. In Japan, dupi[INVESTIGATOR_208433] (PMDA) approval on 26 March 2019 for use in a dults and adolescents 
(≥12 years) with severe or re fractory bronchial asthma. 
Dupi[INVESTIGATOR_208434]  2 mediated immune disorders 
including AD, bronchial asthma, CRSwNP, and eosinophilic esophagitis. In patients with 
moderate to severe uncontroll ed asthma, dupi[INVESTIGATOR_208435] 46 to 70%, and c onsistently improved lung function (FEV 1), including in 
oral corticosteroid dependent pa tients with severe asthma, in whom despi[INVESTIGATOR_040] a reduction in oral 
corticosteroid use, an improvement of 220 ml compared to placebo was observed. A subgroup 
analysis of “COPD-like” patients (eg, patients with age of onset as thma >40, prior smoking 
history, and post-bronchodilator FEV 1/forced vital capacity [FVC]<0.7) included in the Phase 3 
asthma study (Study EFC13579; QUEST) showed s imilar treatment effect s in this subpopulation 
compared to the overall population. 
For dupi[INVESTIGATOR_12458], the safety data observed so far in  completed and currently ongoing studies in AD, 
CRSwNP, and asthma patients (at the same or higher doses than that proposed for this study) have 
demonstrated a satisfactory safety profile. Cons idering the high mortality of COPD patients, all 
Amended Clinical Trial Protocol [ADDRESS_248846]-2023 
Version number: [ADDRESS_248847] an Adjudication Committee for the af orementioned events and a Data Monitoring 
Committee (DMC), which will review the benefit risk including the cardi ac safety on a regular 
basis. 
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of dup ilumab may be found in the Investigator’s Br ochure, Participant 
Information Leaflet, Package In sert, Development Safety Update  Report or Summary of Product 
Characteristics. The Sponsor also recognizes that the “Corona virus Disease 2019” (C OVID-19) pandemic may 
have an impact on the conduct of clinical trials .  The Sponsor will monitor the situation closely 
and ensure the integrity of the trial conduct and data (see Section  8). 
Amended Clinical Trial Protocol [ADDRESS_248848]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 27 3 OBJECTIVES AND ENDPOINTS  
Table 1 - Objectives and endpoints  
Objectives Endpoints 
Primary 
To evaluate the efficacy of dupi[INVESTIGATOR_12458] 300 mg 
q2w in patients with moderate or severe COPD as measured by 
 Annualized rate of acute moderate or severe COPD exacerbation 
(AECOPD).  Annualized rate of moderate* or se vere** COPD exacerbations over 
the 52-week treatment period compared to placebo. 
*Moderate exacerbations are recorded by [CONTACT_208515] 
(such as intramuscular, intravenous or oral) and/or antibiotics.  
**Severe exacerbations are reco rded by [CONTACT_208516][INVESTIGATOR_059], or observation for >24 hours in an emergency department/urgent care facility or resulting in death. 
For both moderate and severe events to be counted as separate events, they must be separated by [CONTACT_2669] [ADDRESS_248849] of dupi[INVESTIGATOR_12458] 300 mg q2w on 
 Pre-bronchodilator forced expi[INVESTIGATOR_3741] 1 second (FEV
1) over 12 weeks compared to 
placebo. 
 Health related quality of life, assessed by [CONTACT_63202] [ADDRESS_248850]. George’s Respi[INVESTIGATOR_6004] (SGRQ). 
 Pre-bronchodilator FEV
1 over 52 
weeks compared to placebo.  Change in pre-bronchodilator FEV 1 from baseline to Week 12 
compared to placebo. 
 Change from baseline to Week 52 in SGRQ total score compared to 
placebo. 
 Proportion of patients with SGRQ improvement ≥4 points at Week 
52. 
 Change in pre-bronchodilator FEV 1 from baseline to Week 52 
compared to placebo. 
Other Secondary 
Evaluate the effects of dupi[INVESTIGATOR_12458] 300 mg 
q2w on lung function assessments.  Change in pre-bronchodilator FEV 1 from baseline to weeks other 
than 12 and 52 (ie, Weeks 2, 4, 8, 24, 36, and 44) compared to placebo. 
 Change in post-bronchodilator FEV
1 from baseline to Week 2, 4, 8, 
12, 24, 36 and 52 compared to placebo. 
 Change in forced expi[INVESTIGATOR_10229] (FEF) 25-75% from baseline to Weeks 2, 4, 8, 12, 24, 36, 44, and 52. 
Evaluate the effect of dupi[INVESTIGATOR_208436].  Annualized rate of severe COPD exacerbations compared to 
placebo over the 52-week treatment period. 
 Time to first moderate or severe COPD exacerbation compared with placebo during the 52-week treatment period.  
Safety and Immunogenicity 
 To evaluate safety and tolerability. 
 To evaluate dupi[INVESTIGATOR_208437] (ADA).
  Adverse events (AEs)/treatment-eme rgent adverse events (TEAEs). 
 Potentially clinically signifi cant laboratory abnormalities in 
hematology, biochemistry and urinalysis. 
 ADA against dupi[INVESTIGATOR_12458]. 
Amended Clinical Trial Protocol [ADDRESS_248851]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 28 Objectives Endpoints 
Tertiary/exploratory 
To evaluate the drug concentration of 
dupi[INVESTIGATOR_208438].  Serum functional dupi[INVESTIGATOR_208439].  
To explore the association of biomarkers with 
treatment response.   Pharmacodynamic response of selected biomarkers. 
- Pulmonary and activation-regulated chemokine (PARC). 
- Eotaxin-3. 
- Fractional exhaled nitric oxide(  FeNO; postbronchodilator). 
- Total IgE. 
 Fibrinogen. 
 Optional: Messenger ribonucleic acid  (mRNA) sequencing or whole 
transcriptome analysis from blood. 
 Optional: Deoxyribonucleic acid  (DNA) for assessment of 
pharmacogenomic effects. 
Predictive effects of selected biomarkers on treatment response.  
To evaluate the effects of dupi[INVESTIGATOR_208440] 1 and FVC.   Annualized loss of lung function as assessed by a FEV 1 slope 
analysis. 
 Change from baseline in FVC (% predicted and absolute values in 
mL) from baseline to Week 12, Week 24 and Week 52. 
To evaluate the effects of dupi[INVESTIGATOR_208441] (EXACT).
  Evaluation of clinical respi[INVESTIGATOR_208442] (E-RS: COPD)  
comprised in the EXACT tool. 
 Annualized rate of COPD exacerbations assessed by [CONTACT_208527] 52 week. 
To evaluate the effects of dupi[INVESTIGATOR_208443].
  Increase in number of controller medication after exacerbation. 
 Increase in patient total daily dose of controller medication after 
exacerbation. 
3.[ADDRESS_248852]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 29 4 STUDY DESIGN  
4.1 OVERALL DESIGN  
Multinational, randomized, double-blind, placebo-controlled, parallel groups (2 groups), 52-week 
Phase 3 study to assess the efficacy, safety, a nd tolerability of dupi[INVESTIGATOR_208408]-to-severe Type 2 inflammatory COPD su ch as that driven by [CONTACT_208523]-4, IL-5, 
and IL-13 on an established LA BA, LAMA and/or ICS background therapy (triple therapy unless 
ICS contraindicated). Study tr eatments are dupi[INVESTIGATOR_12458] [ADDRESS_248853] bo q2w administered 
during the 52-week treatment period.  The study includes 3 study periods. 
 Screening period (4 weeks ±1 week). 
 Randomized investigational medicinal pr oduct (IMP) treatment period (52 weeks 
±3 days). 
 Post IMP treatment period  (12 weeks ±5 days). 
Patients who satisfy the in clusion and exclusion crit eria will be randomized (1:1) to one of the 
following IMP treatment period groups to be administere d for 52 weeks: 
 Dupi[INVESTIGATOR_12458] 300 mg, ad ministered as 1 SC injection q2w. 
 Placebo administered as 1 SC injecti on of placebo matching dupi[INVESTIGATOR_12458] 300 mg. 
Randomization will be stratified by [CONTACT_1606], ICS dos e (high dose ICS [yes/no]) at baseline, and 
smoking status at screening (current smokers or not). As an exam ple, the adult high dose of ICS 
for fluticasone propi[INVESTIGATOR_28321] >500 mcg (DPI [INVESTIGATOR_208444]) or 401-800 mcg (HFA) for Japanese 
population (please refer to Section  10.[ADDRESS_248854] common ICS). 
Alerts will be built into the in teractive voice/web res ponse system (IVRS/IWRS)  to limit enrolling 
patients who are current smokers (a s defined by [CONTACT_208528]) to less than or equal 
to 30% or 278 patients out of  the total enrolled patients. 
Study intervention disc ontinuation follow-up 
Patients who discontinue the study intervention pr ematurely (prior to completing the 52-week 
treatment period) will perform, as  soon as possible, the early treatment discontinuation (ETD) 
visit with all assessments normally planned for th e end of treatment (EOT) visit, to assure a 
complete clinical assessment in  close temporal proximity to th e premature termination of study 
treatment is available. In addi tion, to allow assessment of patie nt outcomes over the stipulated 
study period, patients will be asked and encouraged to complete all remaining study visits, and participate in all safety follow-up assessments acco rding to the visit schedule. For these patients 
the assessment schedule will be reduced (see Section  1.3.2) and visits during the planned 
treatment period may be conducted by [CONTACT_648] (except for planned EOT) if pa tient is unable to 
come in for a site visit. Asse ssments not completed via phone s hould be performed at the next 
scheduled visit. 
Amended Clinical Trial Protocol [ADDRESS_248855]-2023 
Version number: [ADDRESS_248856] IMP-treatment follow-up: 
Upon completing the 52-weeks randomized IMP treat ment period, patients will continue their 
triple background ICS/LABA/LAMA therapy (unle ss ICS is contraindicated) and enter 12-week 
safety follow-up period. Adjustment of background medication will be allowed at the discretion of 
the Investigator as clinically indi cated during the post- treatment period. 
4.[ADDRESS_248857] been employed for recent studies with other biologics and are considered “state-of-the-art” 
for studies in COPD (16 , 17). The selection of the dose of IM P and duration of study treatment are 
explained in Section  4.[ADDRESS_248858] while significantly reduc ing exacerbations and improving lung function in a 
population of severe corticoste roid-dependent asthmatics. 
In the dupi[INVESTIGATOR_208445], doses of 200 mg q2w and 300 mg q2w demonstrated 
comparable efficacy and safety in re ducing exacerbations and improving FEV
1 in patients with 
moderate-to-severe asthma not chronically using concomitant oral corticosteroids (OCS). 
However, analysis of the exposure-response relati onships using descriptive exposure quartile and 
model-based analyses for these two efficacy  endpoints showed th at increasing dupi[INVESTIGATOR_208446] a greater ef fect for both efficacy endpoints in patients with uncontrolled 
moderate-to-severe asthma. The lung functi on improvement and severe exacerbation rate 
reduction approached a maximum at the exposur e of 200 mg and 300 mg q2w, with a 5 to 9% 
greater reduction in exacer bations for 300 mg q2w. FEV 1 response was also predicted to be better 
maintained over the dosing interval for 300 mg q2w. In severe OC S-dependent asthma patients, 
an exposure response relationshi p was noted at 300 mg q2w, with more patients achieving 
OCS-free asthma control at the e xposure range at 300 mg q2w (mean C trough approximately 
70 mg/L) than that at  200 mg q2w (mean C trough approximately 39 mg/L).  Furthermore, the  
[ADDRESS_248859]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 31 Considering that the proposed CO PD population to be enrolled in this study has the potential for 
significant risk for morbidity a nd mortality associated with im pairment of their lung function, 
similar to the patients in the OCS-sparing Phase 3 asthma study (Study EFC13691), the Sponsor is 
including the 300 mg q2w dose regimen to achieve the optimal benefit/risk rati o in this difficult to 
treat COPD patie nt population. 
4.[ADDRESS_248860] completed the study if he/she  has completed al l phases of the 
study including the end of study visit. 
The end of the study is defined as completion of the last patient last visit (the  End of Study Visit) 
which will occur at the end of a 12-week safety follow-up period for those patients who complete 
the study as per protocol. 
For patients who permanently di scontinue the planned treatmen t, the recommended follow-up is 
described in Section  4.1. 
Amended Clinical Trial Protocol [ADDRESS_248861]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 32 5 STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and en rollment criteria, also known as 
protocol waivers or exem ptions, is not permitted. 
5.1  INCLUSION CRITERIA  
Participants are eligible to be included in the study only if all of the following criteria apply: 
Age 
I 01. Participant must be ≥40 to ≤85 years of age, at the time of signing the informed consent. 
Type of participant and disease characteristics I 02. Participants with a physician diagnosis of COPD who meet the fo llowing criteria at 
screening: 
 Current or former smokers with a smoking history of ≥10 pack-years. 
- Current smokers are defined as those patients who are active smokers with 
≥10 pack-years of smoking (active smoking in cludes cigarettes, e-cigarettes, cigars, 
pi[INVESTIGATOR_27442], etc). 
- Former smokers are defined as those patients who were active smokers with 
≥10 pack-years of smoking (active smoking in cludes cigarettes, e-cigarettes, cigars, 
pi[INVESTIGATOR_27442], etc) and who have stopped smoking for at least 6 months prior to Visit 1. 
 Moderate to severe COPD (post-bronchodilator FEV
1/FVC ratio <0.[ADDRESS_248862]-bronchodilator FEV 1 % predicted >30% and ≤70%). 
 Medical Research Council (MRC) Dyspnea Scale Grade ≥2. 
 Patient-reported history of si gns and symptoms of chronic bronchitis (chronic productive 
cough) for 3 months in the year up to screen ing in the absence of other known causes of 
chronic cough. 
 Documented history of high exacerbation ri sk defined as exacerbation history of 
≥2 moderate* or ≥ 1 severe** within the year prior to inclusion. 
At least one exacerbation should have o ccurred while the patient was taking 
ICS/LAMA/LABA (or LAMA/LABA if ICS is contradicted). 
* Moderate exacerbations are recorded by [CONTACT_941] I nvestigator and defined as AECOPD that require 
either systemic corticosteroids (intramuscular (IM), intravenous, or oral) and/or antibiotics. 
One of the two required moderate exacerbati ons has to require the use of systemic 
corticosteroids. 
** Severe exacerbations are recorded by [CONTACT_208529][INVESTIGATOR_208447] >24 hours in emergency department/urgent care facility. 
 Background triple therapy (ICS + LABA + LAMA) for 3 months prior to randomization 
with a stable dose of medication for ≥1 month prior to Visit 1:  (Double therapy: LABA + 
LAMA allowed if ICS is contraindicated). 
I 03. Evidence of Type 2 inflammation:  Patients with blood eosinophils ≥300 cells/microliter at 
Visit 1 (Screening). 
Amended Clinical Trial Protocol [ADDRESS_248863]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 33 Weight 
I 04. Body mass index (BMI) ≥16 kg/m2. 
Sex I 05. Male or Female. 
Contraceptive use by [CONTACT_208530] w ith local regulations regarding the methods of 
contraception for those participating in clinical studies.   
a) Female participants: A female participant is e ligible to participate if she is not pregnant 
(see Appendix 4 [Section  10.4], not breastfeeding, and at  least one of the following 
conditions applies: 
- Not a woman of childbearing potentia l (WOCBP) as defined in Appendix 4 
(Section  10.4), 
OR 
- A WOCBP who agrees to follow the c ontraceptive guidance in Appendix 4 
(Section  10.4) during the intervention period and for at least [ADDRESS_248864] dose of study intervention. 
Informed  Consent 
I 06. Capable of giving signed informed co nsent as described in Appendix 1 (Section  10.1.2) 
which includes compliance with the requirement s and restrictions list ed in the informed 
consent form (ICF) and in this protocol. 
5.2 EXCLUSION CRITERIA   
Participants are excluded from the study if  any of the following criteria apply: 
Study methodology E 01. COPD diagnosis for less than 12 months prior to randomization. 
E 02. A patient with current diagnosis of asthma or history of asthma according to the Global 
Initiative for Asthma (GINA) guidelines, or other accepted guidelines. 
E 03. Significant pulmonary disease ot her than COPD (eg, lung fibros is, sarcoidosis, interstitial 
lung disease, pulmonary hypertension, bronchi ectasis, Churg-Strauss Syndrome, etc) or 
another diagnosed pulmonary or systemic disease associated with elevated peripheral 
eosinophil counts. 
E 04. Cor pulmonale, evidence of right cardiac failure. 
E 05. Long-term treatment with oxygen >4.0 L/min OR  if a participant requires more than 
2.0 L/min in order to main tain oxygen saturation >88%. 
E 06. Hypercapnia requiring BiPAP. 
E 07. Acute exacerbation of COPD (A ECOPD, as defined above in I 02) within [ADDRESS_248865]-2023 
Version number: [ADDRESS_248866] inf ection within 4 weeks prior to screening, or  during the screening 
period. 
E 09. History of, or planned pneum onectomy or lung volume reduc tion surgery. Patients who are 
participating in the acute phase of a pulm onary rehabilitation program, ie, who started 
rehabilitation <4 weeks prior to screening (N ote: patients in the maintenance phase of a 
rehabilitation program can be included). 
E 10. Diagnosis of α -1 anti-trypsin deficiency. 
E 11. Inability to follow the procedures of the study (eg, due to language problems, 
psychological disorders) or unabl e to read, understand and fill out a questionnaire or use an 
e-Diary without any help. 
E 12. Anti-immunoglobulin E (IgE) therapy (omalizumab ) within 130 days prior to Visit 1 or 
any other biologic therapy (including anti -IL5 mAb) or immunosuppressant to treat 
inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory 
bowel disease, primary biliary cirrhosis, systemic lupus erythe matosus, multiple sclerosis, 
etc.) as well as other diseases within 2 months or 5 half-lives prior to Visit 1, whichever is 
longer. 
E 13. Exposure to another investiga tive drug (small molecules as well as monoclonal antibodies) 
within a time period prior to Visit 1 that is less than 6 months. The minimum interval since 
exposure to any other (non-anti body) investigative study medicat ion is 30 days prior to 
Visit 1. 
E 14. History of systemic hypersensit ivity or anaphylaxis to any biologic therapy, including any 
excipi[INVESTIGATOR_840]. 
E 15. Patients receiving medication or therapy th at are prohibited as concomitant therapy 
(see Section  6.5). 
E 16.  Patient is the Investigator, or any Sub-Inves tigator, research assistant, pharmacist, study 
coordinator, other staff or relative thereof directly involve d in the conduct of the study. 
E 17. Clinically significant abnormal electrocardiogram (ECG) at  randomization that may affect 
the conduct of the study in the judgment of the Investigator , eg, prolonged QTc interval 
[male >450 msec, female >470 ms ec, Fredericia correction]. 
E 18.  A patient with a history of cl inically significant renal, hepatic, cardiovascular, metabolic, 
neurologic, hematologic, ophthalm ologic, respi[INVESTIGATOR_696] (other th an COPD), gastrointestinal, 
cerebrovascular disease/condition, substance and/or alcohol abuse disorder, or history of or 
current other significant medica l illness or disorder whic h, in the judgment of the 
Investigator, could interfere w ith the study or require treatment  that might interfere with 
the study. Specific examples include but 
are not limited to poorly controlled 
insulin-dependent diabetes , uncontrolled hypertension. 
Prior history of malignancy or  active malignancy, including lymphoproliferative diseases 
(except successfully treated ca rcinoma in-situ of the cervix, non-metastatic squamous cell 
or basal cell carcinoma of the skin) within [ADDRESS_248867]-2023 
Version number: [ADDRESS_248868] that the patient has been adequately 
treated and can now start treatment with a bi ologic agent, in the medical judgment of the 
Investigator and/or infectious  disease specialist. Tuberculos is testing will be performed on 
a country-by-country basis, according to local guidelines if required by [CONTACT_173898]. 
E 20. Acute myocardial infarction <6 months from screening visit. 
E 21. TIA or stroke <6 months  from screening visit. 
E 22. Hospi[INVESTIGATOR_208448] <[ADDRESS_248869] 6 months,  
eg, antiarrythmics, antihypertensives, and antidiuretics, etc. Dose modification of 
cholesterol-modifying agents a nd anticoagulants is allowed. 
E 25. Cardiac arrhythmias including pa roxysmal (eg, intermittent) at rial fibrillation are excluded. 
Patients with persistent atrial fibrillation as defined by c ontinuous atrial fibrillation for at 
least 6 months and controlled with a rate c ontrol strategy (ie, sele ctive beta blocker, 
calcium channel blocker, pacemaker placement , digoxin or ablation therapy) and stable 
appropriate level of anticoagul ation for at least 6 months ma y be considered for inclusion. 
E 26. Unstable ischemic heart disease or other relevant cardiovascular disorder such as 
pulmonary embolism, deep vein thrombosis within ≤6 months from enrollment that in 
Investigator's judgment may put the patient at risk or negati vely affect the study outcome. 
E 27.  Patients who are <80% compliant with controller therapy during screening. 
E 28. Previous use of dupi[INVESTIGATOR_12458]. 
E 29. Females who are lactating, breas tfeeding or who are pregnant. 
E 30. Women of childbearing potenti al (pre-menopausal female biologically capable of 
becoming pregnant) who (also see Appendix 4, Section  10.4): 
- Do not have a confirmed negative serum beta -hCG test at Visit [ADDRESS_248870] at Visit 2. 
- Who are not willing to use one of the accepta ble forms of effective contraception for 
the duration of the study as per Table 14 (Appendix 4). 
- Postmenopausal women (defined as at leas t 12 consecutive months without menses) 
are not required to use additional contraception. 
E 31. Diagnosed active parasitic infection (helmint hes), suspected or hi gh risk of parasitic 
infection, unless clinical and (if n
ecessary) laboratory assess ments have ruled out active 
infection before  randomization. 
E 32. History of HIV infection or posit ive HIV 1/2 serology at Visit 1. 
E 33. Known or suspected histor y of immunosuppression, including history of invasive 
opportunistic infections (eg, histoplasmosis, listerios is, coccidioidomycosis, 
pneumocystosis, aspergillosis), despi[INVESTIGATOR_208449]; or unusually frequent, 
recurrent or prolonged infections , per Investigator’s judgment. 
Amended Clinical Trial Protocol [ADDRESS_248871]-2023 
Version number: [ADDRESS_248872] received  antiviral treatment  
(eg, influenza receiving only symptomatic treatment).  
E 35. Live, attenuated vaccinations within 4 weeks prior to Visit 1 or planned live, attenuated 
vaccinations during the study; see Section  10.7 (Appendix 7) for list  of prohibited live, 
attenuated vaccines. 
E 36. Patients with active autoimmune disease or pa tients using immunosuppressive therapy for 
autoimmune disease (eg,  inflammatory bowel disease, pr imary biliary cirrhosis, systemic 
lupus erythematosus, multiple sclerosis, etc). 
E 37. Patients with any of the fo llowing result at screening: 
- Positive (or indeterminate) HBsAg or 
- Positive IgM HBc Ab or 
- Positive total HBc Ab confirmed by [CONTACT_125447] 
- Positive HCV Ab confirmed by [CONTACT_125448]. 
E 38. Clinically significant labora tory tests at screening: 
- Alanine transaminase (ALT) >3 times upper limit of normal range (ULN). 
- Hemoglobin <10 g/100 mL for male and <9 g/100 mL for female. 
- Platelets <100 000/mm3. 
- Creatinine ≥150 μ mol/L. 
E 39. Patients on macrolide (eg, azithromycin) thera py, unless on stable therapy for >12 months. 
E 40. Patient who has withdrawn consent before enrollment/randomization. 
E 41. Despi[INVESTIGATOR_208450], enrollment/randomiz ation is stopped at the study level. 
5.[ADDRESS_248873] of this study. 
5.4 SCREEN FAILURES  
Screen failures are defined as participants who c onsent to participate in the clinical study but are 
not subsequently randomly assigned to IMP. A min imal set of screen fa ilure information is 
required to ensure transparent re porting of screen failure particip ants to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publis hing requirements and to respond to queries 
from regulatory authorities. Mini mal information includes demogr aphy, screen failure details, 
eligibility criteria, and any serious adverse event (SAE). 
Patients who are eligible for rescreening may be rescreened once during th e open screening period 
of the study for the following reasons only: 
 In the case of technical malfunction of equipment. 
 Previously did not meet the criter ia for participation in the study. 
Amended Clinical Trial Protocol [ADDRESS_248874]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 37 Retesting of eosinophil values is allowed up to three t imes during the screening period to meet 
inclusion criteria for showing eosinophil count ≥300 cells/microliter ( I 03) before randomization. 
A patient who is unable to complete a successful sp irometry effort as defi ned by [CONTACT_208531] g the screening period of the study. 
There is no requirement for a wa iting period between the screen-fa ilure date and the rescreening 
date. The IVRS/IWRS report will flag rescreened pa tients. Patients that are rescreened must sign a 
new consent form.  If subject is  rescreened, a different patien t identification number will be 
issued, and all Visit [ADDRESS_248875]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 38 6 STUDY INTERVENTION  
Study intervention is defined as any investigational in tervention(s), marketed product(s), placebo, 
or medical device(s) intended to be administe red to a study participan t according to the study 
protocol. 
6.1 STUDY INTERVENTION(S) ADMINISTERED  
Table 2 - Overview of study interventions administered  
Study intervention name [CONTACT_125502][INVESTIGATOR_12458] 300 mg q2w Placebo q2w 
Dosage formulation Dupi[INVESTIGATOR_12458] 300 mg for SC administration is 
supplied as 150 mg/mL solution in 2.25 mL 
prefilled glass syringes to deliver 300 mg in 2.0 mL. Placebo for dupi[INVESTIGATOR_208451]-filled syringe to deliver 2 mL which will match dupi[INVESTIGATOR_12458] 300 mg. 
Unit dose strength(s)/Dosage level(s) 300 mg Not applicable 
Route of administration Subcutaneous injection sites should 
alternate between the upper thighs, 
4 quadrants of the abdomen or the upper 
arms, so that the same site is not injected twice during consecutive injections. Subcutaneous injection sites should alternate between the upper thighs, 
4 quadrants of the abdomen or the upper 
arms, so that the same site is not injected twice during consecutive injections. 
Dosing instructions Every 14 ±3 days Every 14 ±3days 
Packaging and labeling Dupi[INVESTIGATOR_208452]-filled syringe packed in a patient kit box.  Both glass pre-filled syringe and box will be labeled as required per country 
requirement. Placebo will be supplied as one glass 
pre-filled syringe packed in a patient kit box.  Both glass pre-filled syringe and box will be labeled as required per country 
requirement. 
6.1.[ADDRESS_248876](s)  
The investigational medicinal pr oduct (IMP) is administered ever y 14 ±3 days (q2w) during the 
52-week treatment period ( Table 2 ). 
Investigational medicinal product (IMP) will be administered by [CONTACT_737]/health care professional or designee following clinic procedures and blood collection. Patients should be 
monitored for at least [ADDRESS_248877]-2023 
Version number: [ADDRESS_248878] be 
documented in the patient’s study file. Patient in jection should only be performed in the abdomen 
or upper thighs. Patient should also be instruct ed to monitor for any reaction for at least 
30 minutes (or longer per country sp ecific or local site-specific requirements) follo wing injection. 
If the patient cannot take all the allocated IMP kits  at home (eg. due to a storage issue), the DTP 
(Direct to Patient) service can be used or the pati ent may come to the site to pi[INVESTIGATOR_9696]-up the IMP kits. 
For doses not given at the study site , diaries will be provided to r ecord information related to the 
injections. The diary will be kept as source data in the patient’s study file. 
If the patient is unable or unwilling to administer IM P at home, injections can be performed at the 
site; or arrangements can be ma de for qualified site personnel a nd/or health care professionals 
(eg, visiting nurse service) to ad minister IMP for the doses that ar e not scheduled to be given at 
the study site. 
6.1.[ADDRESS_248879](s)  
Background therapy At Screening Visit 1, all patients must be on trip le background therapy, fo r 3 months prior to  
Visit 2/Randomization and at a stable dose of medication for at least 1 month prior to the 
Screening/Visit 1, including triple therapy: LABA + LAMA + ICS (Double 
therapy: LABA + LAMA allowed if ICS is contraindicated). 
Formulation: dry powder inhaler (DPI), mete red dose inhaler (MDI) or pocket nebulizer. 
Route(s) of administra tion: Oral inhalation. 
Dose regimen: As prescribed. 
Throughout the study, patients should continue their established background therapy for COPD, 
including dose and regimen. Patients must be willing to stay on their esta blished background medica tion for COPD throughout 
the duration of the treatment pe riod. After successful management  of an acute exacerbation of 
COPD (eg, with oral corticosteroids and/or antibiotics), all effo rts should be made to resume the 
initial background COPD treatment regimen if in the Investigator’s opi[INVESTIGATOR_208453]. Background medications should not be ad justed during Screening. After [ADDRESS_248880]-treatment period. 
Background therapy will be supplied from the ti me of randomization on by [CONTACT_2728]’s local 
affiliate as locally required or by [CONTACT_21127]. Reimbursement will be provided when deemed necessary 
and as per country regulation. 
Amended Clinical Trial Protocol [ADDRESS_248881]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 40 Reliever Medication 
Reliever medications will be s upplied by [CONTACT_208532]’s local affiliate  as locally required. 
Patients may administer albuterol/salbutamol or le valbuterol/levosalbutamol  or ipratropi[INVESTIGATOR_208454]/short-acting β agonists [SABA] combinations or terbutaline as needed during the 
study. Nebulizer solutions may be used as an alternative delivery method. Formulation: MDI, nebuliz er solutions or DPI. 
Route of administratio n: oral inhalation. 
Dose regimen: as prescribed. Study personnel will convert sa lbutamol/albuterol nebulizer and levosalbutamol/levalbuterol 
nebulizer use as shown on the following tables: 
Table 3 - Reliever medication - Salbutamol/Albuterol nebulizer solution  
Salbutamol/Albuterol Nebulizer Solution - Total Daily Dose (mg) Number of Puffs* 
2.5 4 
5.0 8 
7.5 12 
10 16 
*Conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) corresponds to 4 puffs. 
 Example of salbutamol/albut erol nebulizer-to-puff conversion: Patient received 
3 salbutamol/albuterol nebu lizer treatments (2.5 mg/trea tment) between 7 and 11 AM. 
Total daily =7.5 mg or 12 puffs. 
Table 4 - Reliever medication - Levosalbutamol/Levalbuterol nebulizer solution  
Levosalbutamol/Levalbuterol Nebulizer Solution -Total Daily Dose (mg) Number of Puffs* 
0.63 2 
1.25 4 
2.5 8 
3.75 12 
5 16 
*Conversion factor:  levosalbutamol/levalbuterol nebulizer solution (1.25 mg) corresponds to 4 puffs. 
 Example of levosalbutamol/lev albuterol nebulizer-to-puff co nversion: Patient received 
3 levosalbutamol/levalbuterol nebulizer tr eatments (1.25 mg/treat ment) between 7 and 
11 AM. Total daily =3.[ADDRESS_248882]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 41 Table 5 - Reliever medication - Ipratropi[INVESTIGATOR_208405]/short-acting β agonists [SABA] nebulizer 
solutions  
Total Daily Dose of Ipratropi[INVESTIGATOR_1890] (mg) in Ipratropi[INVESTIGATOR_208405]/SABA 
Nebulizer Solutions  Number of Puffs* 
0.5 4 
1.0 8 
1.5 12 
2.0 16 
*Conversion factor: ipratropi[INVESTIGATOR_208411]/short-acting β agonists (SABA) nebulizer solution (with 0.5 mg Ipratropi[INVESTIGATOR_1890]) corresponds to 
4 puffs. 
 Example of ipratropi[INVESTIGATOR_208411]/SABA nebulizer-t o-puff conversion: Patient 
received 3 ipratropi[INVESTIGATOR_208411]/SABA nebulizer treatments (0.5 mg 
Ipratropi[INVESTIGATOR_1890]/treatment) between 7 and 11 AM. Total daily =1.5 mg or 12 puffs. 
6.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY  
Storage and handling 
Investigators or other authorized persons (eg, pharmacists) are respon sible for storing the 
IMP/noninvestigational medicinal product (NIMP) in  a secure and safe place in accordance with 
local regulations, labeling specifica tions, policies, and procedures. 
Control of IMP storage c onditions, especially control of temperat ure (eg, refrigerated storage) and 
information on in-use stability and instruc tions for handling the [COMPANY_011] compound must be 
managed according to the rules provided by [CONTACT_208533]. 
The expi[INVESTIGATOR_208455] (when required by c ountry regulation), and 
storage conditions are wr itten on the IMP labels. 
1. The Investigator or designee must confirm a ppropriate temperature conditions have been 
maintained during transit for all study in tervention and NIMP received and any 
discrepancies are reported and resolved before use of the study intervention. 
2. Only participants enrolled in  the study may rece ive study intervention and only authorized 
site staff may supply or ad minister study intervention. All study intervention and NIMP 
must be stored in a secure, environmen tally controlled, and monitored (manual or 
automated) area in accordance w ith the labeled storage condit ions with access limited to 
the Investigator and au thorized site staff. 
3. The Investigator, institution, or the head of the medical inst itution (where a pplicable) is 
responsible for study intervention and NIMP  accountability, reconc iliation, and record 
maintenance (ie, receipt, reconciliat ion, and final dis position records). 
4. Further guidance and information for the final disposition of used and unused study 
interventions are provided in a Pharmacy manual. 
Preparation of IMP 
Dupi[INVESTIGATOR_208456]-filled syringes will be dispensed to the patients. 
Amended Clinical Trial Protocol [ADDRESS_248883]-2023 
Version number: [ADDRESS_248884], or other personnel allowed to store and dispense the 
IMP/NIMP will be responsible for ensuring that the IMP/NIMP used in the clinical trial is 
securely maintained as specified by [CONTACT_56446]. 
All IMP/NIMP will be dispensed in accordance with the Investigat or's prescription and it is the 
Investigator's responsibility to en sure that an accurate record of IMP/NIMP issued and returned is 
maintained. For doses not given at study site, the home dosing diary will be used to record 
injections. 
Any quality issue noticed with th e receipt or use of an IMP/ NIMP (deficiency in condition, 
appearance, pertaining documentatio n, labeling, expi[INVESTIGATOR_320], etc) must be promptly notified to 
the Sponsor. Some deficiencies may be recorded through a co mplaint procedure  
(see Section 8.3.9). 
A potential defect in the quality of IMP/NIMP ma y be subject to initiati on of a recall procedure 
by [CONTACT_1034]. In this case, the Investigator wi ll be responsible for promptly addressing any 
request made by [CONTACT_1034], in order to recal l the IMP/NIMP and eliminate potential hazards. 
Under no circumstances will the Investigator supp ly IMP/NIMP to a third party (except for DTP 
shipment, for which a courier co mpany has been approved by [CONTACT_1034], the local regulation 
may apply as well as the particip ant approval), allow the IMP/NIMP/d evice to be used other than 
as directed by [CONTACT_208534], or dispose of IMP/NIMP/device in any other manner. 
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING  
6.3.[ADDRESS_248885] will be ge nerated centrally by [CONTACT_208535]. The 
IMPs (dupi[INVESTIGATOR_181150]) will be pa ckaged in accordance with the list. The [COMPANY_011] 
Clinical Supply Chain team will provide the ra ndomized treatment kit number list and the Study 
Biostatistician will provide the randomization scheme to the centralized treatment allocation 
system (IVRS/IWRS). This centralized treatmen t allocation system will generate the patient 
randomization list according to which it will allocat e the IMPs to the patients. The Investigator 
obtains treatment kit number at randomizati on and subsequent scheduled visits via an 
IVRS/IWRS that will be available 24 hours a day. Patients will be randomized in a 1:1 ratio to 
receive SC administrations of either: 
 Dupi[INVESTIGATOR_12458] 300 mg q2w. 
 Matching placebo for dupi[INVESTIGATOR_12458] q2w. 
Randomization will be stratified by [CONTACT_1606], ICS dos e (high dose ICS [yes/no]) at baseline, and 
smoking status at screening (current smokers or not). As an exam ple, the adult high dose of ICS 
for fluticasone propi[INVESTIGATOR_28321] >500 mcg (DPI [INVESTIGATOR_208444]) or 401-800 mcg (HFA) for Japanese 
population (see Section  10.[ADDRESS_248886] common ICS). Alerts will 
be built into the IVRS/IWRS to limit enrolling patients who are current smokers (as defined by 
[CONTACT_208536] [ADDRESS_248887]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 43 smoking status at screening) to less than or equal to 30% or 278 patients out of the total enrolled 
patients. 
Investigational medicinal products will be disp ensed at the study visits summarized in SoA 
(Section  1.3). 
Returned IMP from the patient’s home should not be re-dispensed to the participants. 
6.3.[ADDRESS_248888] the blind, each treatment kit of 2 mL (dupi[INVESTIGATOR_12458] / placebo) glass pre-filled syringes 
will be prepared such that the treatments (dupi[INVESTIGATOR_208457]) are identical and 
indistinguishable and will be labe led with a treatment kit number. 
In accordance with the double-blind design, study patie nts, Investigators, and study site personnel 
will remain blinded to st udy treatment and will not have access to the randomization arm or to the 
IMP content (dupi[INVESTIGATOR_24885]) except under circ umstances described in Section  6.3.3. 
6.3.[ADDRESS_248889] only be broke n in circumstances when knowledge of the IMP is 
required for treating the patient. 
Code breaking can be performed at any time by [CONTACT_208537]/IWRS 
and/or by [CONTACT_208538] r that purpose. If the blind is 
broken, the Investigator must document the da te, time of day, and r eason for code breaking. 
Patient withdrawal will onl y occur when the code break call is ma de at the site level, not the study 
level. This means that if the Emergency Unblin ding transaction is perfor med by [CONTACT_737] 
(ie, at the site level), then the patient w ill be withdrawn from treatment. However, if the 
Emergency Unblinding transaction is performed by [CONTACT_125460] (GSO) (ie, at the 
study level, as the GSO is not site based), then the patient will not be withdrawn from treatment. 
Patients who are withdrawn from treatment should be encouraged to remain in the study and the 
Investigator should discuss with th em the key visits to attend (see Section  7.2).  
6.[ADDRESS_248890] wi ll also keep accurate records of  the quantities of the IMP/NIMP 
received, dispensed, used, unused and return ed/destroyed. The product accountability and 
inventory form/system is to be updated each time IM P/NIMP is dispensed. It must be established 
with the Investigator or othe r personnel designated by [CONTACT_208539]. The study monitor will period ically check the supplies of 
the IMP held by [CONTACT_208540]. 
Treatment kit number has to be recorded on the appropriate page of the electronic Case Report 
Form (eCRF) and also on the product acc ountability and inventory form/system. 
Amended Clinical Trial Protocol [ADDRESS_248891]-2023 
Version number: [ADDRESS_248892] not destroy the unused 
IMP/NIMP unless the Sponsor provides written aut horization. Confirmation of destruction will be 
provided to the Sponsor. 
6.5 CONCOMITANT THERAPY  
Any medication or vaccine (including over-the-c ounter or prescription medicines, vitamins, 
and/or herbal supplements) that th e participant is receiving at the time of enrollment or receives 
during the study must be  recorded along with: 
 Reason for use. 
 Dates of administration including start and end dates. 
 Dosage information in cluding dose and frequency. 
The following concomitant medications are not  permitted during the study from screening 
onwards: 
 Use of any biologic agent within 5 half-liv es of that compound before study entry 
(6 months if half-life is not known) and during th e course of the study. 
 Use of PDE4 inhibitors (roflumilast) and of theophylline during the course of the study 
unless stable >6 months pr ior to screening visit. 
 New chronic use of macrolide antibiotics (eg, azithromycin) with the exception of 
AECOPD, in which case macrolides may be used up to 28 days.  
 Systemic immunosuppressants (e g, methotrexate, any anti-T NF mAbs, B and/or T-cell 
targeted immunosuppressive therap ies) including chronic use of systemic corticosteroids. 
 Intravenous immunoglobulin (IVIG) therapy. 
 Live attenuated vaccines , refer to Appendix 7 ( Section  10.7). 
 Beta-adrenergic receptor blockers (except fo r a selective beta-1 adrenergic receptor 
blocker used with dose stable  1 month prior to Visit 1). 
 Other investigational drugs. 
Note:  The following is a list of pe rmitted concomitant medications  during the study, refer to 
Section  6.1.2 for expected background thera py and allowed reliever medications. 
 Maintenance treatment of COPD with IC S, LABA, LAMA, at a stable dosage. 
 Systemic corticosteroids in case of acute exacerbation up to a maximum of 6 weeks. 
 Rescue medication with SABA or shor t acting antimuscarinics (eg, atrovent). 
6.6 DOSE MODIFICATION  
Not applicable. 
6.7 INTERVENTION AFTER THE END OF THE STUDY  
Upon completion of the treatment period (52 weeks), or after early termin ation, study drug will no 
longer be provided to participants. 
Amended Clinical Trial Protocol [ADDRESS_248893]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 45 7 DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
Withdrawal of consent for treatm ent (ie, treatment discontinuation at patient request) should be 
distinguished from (additiona l) withdrawal of consen t for follow-up visits and from withdrawal of 
consent for non-patient contact [CONTACT_6492]-up (eg, me dical record checks). The site should document 
any case of withdrawal of consent. 
7.1 DISCONTINUATION OF STUDY INTERVENTION   
The IMP should be continued whenever possible. 
In case the IMP is stopped, it shou ld be determined whether the stop can be made temporarily; 
permanent IMP discontinuation should be a last resort. Any IMP discontinuation must be fully 
documented in the eCRF. 
7.1.1 Permanent discontinuation  
In rare instances, it may be necessary for a pa tient to permanently discontinue study intervention. 
If study intervention is permanently  discontinued, the participan t remains in the study to be 
evaluated for as per Section 1.3.2 (see the SOA for data to be collected at the time of 
discontinuation of study intervention). Permanent intervention discontinua tion is any intervention discontinuation associated with the 
definitive decision from the Investigator not to re -expose the patient to the IMP at any time during 
the study, or from the patient not to be re -exposed to the IMP wh atever the reason. 
List of criteria for permanent disc ontinuation of study intervention 
All efforts should be ma de to document the reason(s) for di scontinuation of study intervention and 
this should be documented in the eCRF. Patients must be withdrawn from the study intervention for the following reasons: 
 At their own request or at the request of th eir legally authorized representative (legally 
authorized representative means an individua l or judicial or othe r body authorized under 
applicable law to consent on behalf of a prospe ctive patient to the pati ent's participation in 
the procedure(s) involve d in the research). 
 If, in the Investigator's opi[INVESTIGATOR_1649], cont inuation on the study intervention would be 
detrimental to the patient's well-being. 
 At the specific request of the Sponsor. 
 In the event of a protocol deviation, at the discretion of the Investigator or the Sponsor. 
 Any code broken requested by [CONTACT_208541]. 
 Pregnancy. 
Amended Clinical Trial Protocol [ADDRESS_248894]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 46  Anaphylactic reactions or systemic allergic re actions that are relate d to IMP and require 
treatment. 
 Diagnosis of a malignancy during study, excluding carcinoma in situ of the cervix, or 
squamous or basal cell carcinoma of the skin. 
 Any opportunistic infection, such as TB or ot her infections whose nature or course may 
suggest an immunocompromised status (see Section  10.16, Appendix 16). 
 Serum ALT >[ADDRESS_248895] and Total Bilirubin >2ULN (see Section  10.6, Appendix 6). 
 Serum ALT >[ADDRESS_248896] if baseline ALT ≤[ADDRESS_248897] or ALT >[ADDRESS_248898] if baseline ALT >[ADDRESS_248899] 
(see Section  10.6, Appendix 6). 
 If the patient misses more than 3 consecutive doses, the patient will be permanently 
discontinued from the study intervention. 
Any abnormal laboratory value or ECG parameter will be immediately rechecked for 
confirmation before making a deci sion of permanent discontinuation of the IMP for the concerned 
patient. 
See the SoA ( Section  1.3.2) for data to be collected at the time of intervention discontinuation and 
follow-up and for any further evaluati ons that need to  be completed. 
Handling of participants after perman ent study intervention discontinuation  
Patients who discontinue the study intervention pr ematurely (prior to completing the 52-week 
treatment period) will perform, as soon as possibl e, the ETD visit with all assessments normally 
planned for the EOT visit (Visit 16), to assure a complete clinical assessment in close temporal 
proximity to the premature term ination of study treatment is av ailable. In addition, to allow 
assessment of patient outcomes over the sti pulated study period, patients will be asked and 
encouraged to complete all re maining study visits, and particip ate in all safety follow-up 
assessments according to the visit schedule with  a ±5-day window. For these patients the 
assessment schedule will be reduced (see Section  1.3.2) and visits during the planned treatment 
period may be conducted by [CONTACT_648] (except for planned EOT) if patient is una ble to come in for a 
site visit. Assessments not comp leted via phone should be performed at the next scheduled visit. 
Patients will be followed-up according to the study pr ocedures specified in this protocol up to the 
scheduled date of study co mpletion (ie, EOS, see Section  1.3), or up to recovery or stabilization of 
any AE to be followed-up as specified in this protocol, whichever comes last. 
Patients who discontinue early from treatment may be asked to return to the clinic to have 
additional antidrug antibody (ADA) samples co llected for analysis  based on the overall 
assessment of antibody titers a nd/or clinical presentation at  the time of discontinuation. 
All cases of permanent discontinuation of study intervention should be recorded by [CONTACT_208542]. 
Amended Clinical Trial Protocol [ADDRESS_248900]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 47 7.1.2 Temporary discontinuation of study intervention   
Temporary discontinuation of study intervention may be consider ed by [CONTACT_208543]. Reinitiation of treatment with the IMP w ill be done under close and appropriate clinical/and 
or laboratory monitoring once the Investigator will have considered according to his/her best 
medical judgment that AE is su fficiently resolved and unlikely to recur after resuming therapy 
with IMP. 
In addition, the following conditions(s) will be  causes for temporary discontinuation of study 
intervention: 
 Infections or infestations that do not respond to medical treatment. 
 Any laboratory abnormality that meets temporary treatment disc ontinuation criteria as per 
Appendix 6 ( Section  10.6). 
If a patient is unable to return to clinic for a gi ven visit within the specified visit window, patient 
should follow-up with all visit follow-up procedur es planned for the subsequent visit (excluding 
randomization and EOT). If more than [ADDRESS_248901] on-s ite scheduled visit, then 
unscheduled visit is required wi thin 3 weeks of missed scheduled visit (eg, if missed scheduled 
visit at Week 24, then unscheduled visit must be  performed by [CONTACT_10585] 27; if missed scheduled visit 
at Week 36, then unscheduled must be performed by [CONTACT_10585] 39). All the asse ssments of the missed 
scheduled on-site visit will need to be carried out at the unscheduled visit. For all temporary disc ontinuations of study intervention, du ration must be recorded by [CONTACT_208544]. Following a temporary interruption or missed do se, the IMP treatment 
should be reinitiated at the next schedul ed dose, maintaining the original dose. 
7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY  
A participant may withdraw fro m the study at any time at his/ her own request, or may be 
withdrawn at any time at the discretion of the In vestigator for safety, be havioral, compliance, or 
administrative reasons. 
 If the participant withdraws consent for disclo sure of future information, the Sponsor may 
retain and continue to use any data collect ed before such a wit hdrawal of consent. 
 If a participant withdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the I nvestigator must document this  in the site study records.  
 See SoA ( Section  1.3.2) for data to be collected at  the time of study discontinuation and 
follow-up and for any further evaluati ons that need to  be completed. 
Patients who withdraw from study treatment (prior to completing the plan ned duration of IMP 
treatment) will perform the ETD visit and will be as ked and encouraged to complete all remaining 
study visits. Patients who withdraw  from the study during the pos t-treatment phase should be 
encouraged to return for th e EOS visit (for details see Section  1.3.2 and Section  7.1.1). The value 
of all their study data collect ed during their continued involvement will be emphasized as 
important to the public h ealth value of the study. 
Amended Clinical Trial Protocol [ADDRESS_248902]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 48 All study withdrawals should be re corded by [CONTACT_56479] 
e-CRF, IVRS/IWRS and in the patient’s medical reco rds. In the medical record, at least the date 
of the withdrawal and the r eason should be documented. 
In addition, a patient may withdr aw his/her consent to  participate in the study. Withdrawal of 
consent for intervention should be distinguished from withdrawal of  consent for follow-up visits 
and from withdrawal of consent for non-patient contact [CONTACT_6492]-up, eg, medical record checks. The 
site should document any case of withdrawal of consent. 
Participants who have withdr awn from the study cannot be rera ndomized (treated) in the study. 
Their inclusion and intervention numbers must not be reused. 
If possible, the patients are assessed using the procedure normally plan ned for the end-of-study 
visit including a systemic drug conc entration sample, if appropriate,  and the Post treatment Period 
Visits. 
7.[ADDRESS_248903] be taken if a participant fails to return to the c linic for a required study 
visit: 
 The site must attempt to contac t the participant and reschedule the missed visit as soon as 
possible and counsel the participant on the importance of maintain ing the assigned visit 
schedule and ascertain whether or  not the participant wishes to  and/or should continue in 
the study. 
 Before a participant is  deemed lost to follow up, the Inve stigator or designee must make 
every effort to regain contact [CONTACT_6635] (where possi ble, 3 telephone calls and, if 
necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact [CONTACT_24101]’s 
medical record. 
 Should the participant continue to be unreach able, he/she will be considered to have 
withdrawn from the study. 
Amended Clinical Trial Protocol [ADDRESS_248904]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 49 8 STUDY ASSESSMENTS  AND PROCEDURES  
Study procedures and their timing are summarized in the SoA (Section  1.3). Protocol waivers or 
exemptions are not allowed. 
 Immediate safety concerns should be di scussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should cont inue or discontinue 
study intervention. 
 Adherence to the study design requirements, including those specified in the SoA, is 
essential and require d for study conduct. 
 All screening evaluations must be complete d and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator will maintain a screening log to 
record details of all participants screened a nd to confirm eligibility or record reasons for 
screening failure, as applicable. 
Procedures conducted as part of the participan t’s routine clinical ma nagement (eg, blood count) 
and obtained before signing of the ICF may be utilized for screening or baseline purposes 
provided the procedures met the pr otocol-specified criteria and we re performed within the time 
frame defined in the SoA ( Section  1.3). 
In light of the public health emergency related to COVID-19 (o r in case of any other pandemic 
requiring public health emergenc y), the continuity of clinical  study conduct and oversight may 
require implementation of temporary or alternative mechanisms , eg, phone contact,  virtual visits, 
online meetings, use of local clinic or laborat ory locations, and home vi sits by [CONTACT_25011]. 
Implementation of such mech anisms may differ country by [CONTACT_1606], depending on country 
regulations and local business cont inuity plans. Additionally, no wa ivers to deviate from protocol 
enrollment criteria due to COVID-19 (or any other pandemic) will be granted. All temporary 
mechanisms utilized, and deviat ions from planned study procedures  in response to COVID-[ADDRESS_248905] only for the duration of 
the public health emergency. 
8.1 EFFICACY ASSESSMENTS   
8.1.1 Disease-specific efficacy measures  [IP_ADDRESS] Severity of COPD exacerbations as defined by [CONTACT_760]  
“Moderate exacerbations” are recorded by [CONTACT_208545] (such as intramuscular, intr avenous or oral) and/or antibiotics. 
“Severe exacerbations” are reco rded by [CONTACT_208529][INVESTIGATOR_059], or observation for >24 hours in emergency departme nt/urgent care facility or 
resulting in death. 
All other exacerbations will be classified as “mild”. 
For both moderate and severe events to be counted  as separate events, they must be separated by 
[CONTACT_2669] [ADDRESS_248906]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 50 Clinical symptoms of exacerbations of COPD 
In addition to the protocol-defined exacerbati ons of COPD listed above, clinical signs and 
symptoms of exacerbations of COPD will be capt ured in the eCRF (including, but not limited to 
increase in dyspnea, increase in wheezing, incr ease in cough, increase in sputum volume and/or 
increase in sputum purulence). Management of exac erbations of COPD 
Exacerbations of COPD should be treated as  deemed necessary by [CONTACT_737]. 
After successful management of an acute exacer bation of COPD (eg, with oral corticosteroids 
and/or antibiotics), all efforts s hould be made to resume the in itial background COPD treatment 
regimen if in the Investigator’s opi[INVESTIGATOR_208458]. After 1 severe or 2 moderate 
exacerbations of COPD, dose adjustments in bac kground therapy will be permitted for symptom 
control and as needed for the remainder of the trial period. 
Protocol defined COPD exacerbation events ar e collected as efficacy endpoints via the 
exacerbation eCRF. These events should not be re ported as AEs unless they fulfill a seriousness 
criterion. 
[IP_ADDRESS] Spi[INVESTIGATOR_208459] (ERS)/American Thoracic Society (ATS) guidelines ( 22) and prior to 
administration of investigational product. 
For pre-bronchodilator measur ed parameters, including FEV 1, FVC and forced expi[INVESTIGATOR_10229] 
(FEF) 25%-75%, spi[INVESTIGATOR_208460] a wash out peri od of bronchodilators 
according to their action duration, for example, w ithholding the last dose of salbutamol/albuterol 
or levosalbutamol/levalbute rol for at least [ADDRESS_248907] 
12 hours (ultra-long acting LABA lik e vilanterol should be withhe ld for at least 24 hours), 
withholding the last dose of ipra tropi[INVESTIGATOR_208461] [ADDRESS_248908] 24 hours. This will be verified before perfor ming the measurements. 
Note: When both pre- and post- bronchodilator spi[INVESTIGATOR_208414], the post-bronchodilator 
spi[INVESTIGATOR_208462] d consistent with the mechan ism of action of reliever  
(ie, 30 minutes for albuterol or another SABA). 
At all visits, spi[INVESTIGATOR_208463] e morning; afternoon/evening is 
allowable in the exceptional circumstance when  morning spi[INVESTIGATOR_125375]; 
spi[INVESTIGATOR_208464]. 
Current smokers need to be re minded not to smoke for at le ast [ADDRESS_248909]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 51 Further details on spi[INVESTIGATOR_181203]  a separate operational manual provided to the 
sites. 
8.1.2 Clinical outcome assessments  
[IP_ADDRESS] Patient reported outcome questionnaires  
At screening (Visit 1), patients will be issued an electronic diary. Patients  will be instructed and 
trained by [CONTACT_208546] e of the device, and written instructions on the 
use of the electronic device will be provided to the patients. Reco rded information is downloaded 
from this device on the other indicated days ( Section  1.3). 
On a daily basis during screening and treatment , the patient will use an electronic diary to: 
 Respond to the COPD exacerbation and sympto m scale questions of the EXACT tool. 
 Record use of established c ontroller inhala tion therapy. 
The electronic diary will be us ed for other patient related ques tionnaires such as SGRQ from the 
protocol. 
In the Post IMP Treatment Peri od, the patient's respons e in the electronic  diary will not be 
recorded daily; electronic questionnaires will only be administered at on-site visits as outlined in 
the SoA. Patient-reported outcome questionna ires at a site visit should be  completed prior to any other 
assessments or procedures. 
[IP_ADDRESS].1 St. George's Respi[INVESTIGATOR_6015] (SGRQ)  
The St. George's Respi[INVESTIGATOR_208465] (SGRQ [ 23, 24]) is a 50-item quest ionnaire designed 
to measure and quantify health status in adult patients with chronic airflow limitation. A global 
score ranges from 0 to 100. Scores by [CONTACT_208547] n are calculated for th ree domains: Symptoms, 
Activity and Impacts (Psycho-social) as well as a total score. Lower score indicates better quality 
of life (QoL) (see Appendix 10: St. George's Respi[INVESTIGATOR_6015],  
Section  10.10). 
The first part ("Symptoms") evaluates symptomatology, including frequency and severity of 
cough, sputum production, wheeze, breathlessness and the duration and frequency of attacks of 
breathlessness or wheeze. The second part ha s two components: "Activity" and "Impacts". 
The "Activity" section addresses disturbances to patie nts’ daily physical ac tivities. The "Impacts" 
section covers a range of effe cts that chest troubles may ha ve on patients’ daily life and 
psycho-social functions (eg, daily life activities and f unctioning, employment, physical 
functioning, emotional impact, stig matization, and patients’ perceptio ns when treated). The recall 
period of the questionnaire is over the past [ADDRESS_248910]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 52 [IP_ADDRESS].2 Exacerbations of chronic pulmonary disease tool (EXACT)  
The EXACT tool quantifies and measures exacerb ations of COPD and assesses the symptomatic 
manifestations of these COPD exacerbations  (see Appendix 12: Exacerbations of Chronic 
obstructive pulmonary disease tool [EXACT], Section  10.12). The instrument is a daily diary 
composed of a total of 14 items representing the following domains: 
 Breathlessness (5 items). 
 Cough and sputum (2 items). 
 Chest symptoms (3 items). 
 Difficulty bringing up sputum (1 item). 
 Tired or weak (1 item). 
 Sleep disturbance (1 item). 
 Scared or worried (1 item). 
Development and validation history of the tool is consistent with  guidelines proposed by [CONTACT_1622], 
EMA and well-known measurement principles . The EXACT total score assesses COPD 
exacerbations. The higher the score, th e more severe are the symptoms. 
The Evaluating Respi[INVESTIGATOR_208466] (E-RS) in COPD (E-RS: COPD) scale is a part of the 
EXACT tool. It is a derivative inst rument used to measure the effe ct of treatment on the severity 
of respi[INVESTIGATOR_208467]. The E-RS utilizes the [ADDRESS_248911]. The RS-Total score represents respi[INVESTIGATOR_68138], 
overall. Three subscales can be used that assess : 1) breathlessness (RS-Breathlessness), 2) cough 
and sputum (RS-Cough and Sputum), and 3) ch est-related symptoms (RS-Chest Symptoms). 
The higher the score the more severe are the symptoms. 
[IP_ADDRESS].3 The 5-level Euro Quality of Life-5 Dimension questionnaire (EQ-5D-5L)  
EQ-5D-5L is a standardized health-related QoL questionnaire developed by [CONTACT_159872] a simple, generic measure of health  for clinical and economic appraisal. EQ 5D is 
designed for self-completion by [CONTACT_1962]. The EQ-5D consists of a descriptive system and the EQ 
Visual Analog Scale (VAS). The descriptive sy stem comprises five dimensions: mobility, 
self-care, usual activities, pain/discomfort and anxiet y/depression. Each dime nsion has 5 levels: 
no problems, slight problems, moderate proble ms, severe problems and extreme problems. 
The EQ VAS records the patient’s self-rated health on a vertical visual analogue scale, 
(Appendix 14, see Section  10.14). 
[IP_ADDRESS] Other clinical outcome assessments  
[IP_ADDRESS].1 Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index 
(BODE Index)  
The BODE Index is a composite measure comp osed of a Performance Outcome Measure, a 
Patient-Reported Outcome Measure and a Biomarker. The BODE Index is a multidimensional 
grading system to assess the respi[INVESTIGATOR_208468] ( 25). It comprises  
Amended Clinical Trial Protocol [ADDRESS_248912]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 53 4 domains: 1) Degree of pu lmonary impairment (FEV 1); 2) Patient’s perception of symptoms 
(mMRC); and 2 independent domains: the 6 Minute Walking Distance (6MWD) and the 
Body-Mass Index (BMI). Each domain can be scored independently; the global score ranges from 
0 to 10, with a higher score indicating a higher risk of death (see Appendix 13, Section  10.13). 
8.[ADDRESS_248913] (AESI), will be collected at 
every visit. The assessments for AE , SAE and AESI are described in Section  8.3. 
Planned time points for all safety as sessments are provided in the SoA ( Section  1.3). 
8.2.1 Physical examinations  
A complete physical examination will include skin, nasal cavi ties, eyes, ears, respi[INVESTIGATOR_696], 
cardiovascular, gastrointestinal , neurological, lymphatic, and musculoskeletal systems. All 
deviations from normal will be recorded, including those attributable to the patient’s disease. 
Refer to Section  1.3 for the schedule of physical examin ations performed throughout this study. 
Investigators should pay special atte ntion to clinical signs related to  previous serious illnesses or 
signs of infection. 
Any new clinically significant finding or worsen ing of previous finding s hould be reported as a 
new adverse event. 
8.2.2 Vital signs  
Vital signs, including systolic and diastolic blood pressure (mmHg), pulse rate (beats per minute), 
body temperature (°C), and respi[INVESTIGATOR_208469], baseline and every 
subsequent on-site visit. Height (cm) will be me asured at Screening (Visit 1) only. Body weight 
(kg) will be measured at  Screening (Visit 1) and EOT/EOS visits. Refer to Section  1.[ADDRESS_248914] administration. A minimum of 3 complexes in an 
appropriate lead (lead II) will be averaged to  determine the PR-interval, QT/QTc-interval, 
QRS-complex and heart rate will be measured fo r each ECG; the triplicate ECGs are required. 
Refer to ECG reading manual for more details. All ECG recordings will be centrally read 
by [CONTACT_208548]. 
Amended Clinical Trial Protocol [ADDRESS_248915]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 54 8.2.4 Clinical safety laboratory assessments  
The clinical laboratory tests are planned to be conducte d at a central laboratory. 
See Appendix 2 ( Section  10.2) for the list of clin ical laboratory tests to be performed and to the 
SoA for the timing and frequency. 
The Investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE s ection of the CRF. The 
laboratory reports must be filed with the source documents. C linically significant abnormal 
laboratory findings are those which are not associated with the unde rlying disease, unless judged 
by [CONTACT_208549]'s condition. 
All laboratory tests with values considered clin ically significantly abno rmal during participation 
in the study or within [ADDRESS_248916] dos e of study intervention shou ld be repeated until the 
values return to normal or baseline or are no longer considered clinically significant by [CONTACT_208550]. 
If such values do not return to normal/baseline within a period of  time judged reasonable by [CONTACT_3786], the etiology should be identified and the Sponsor notified. All protocol-required laboratory assessm ents, as defined in Appendix 2 ( Section  10.2), must be 
conducted in accordance with the laboratory manual and the SoA. 
If laboratory values from non- protocol specified laboratory assessments performed at the 
institution’s local laboratory re quire a change in participant management or are considered 
clinically significant by [CONTACT_18413] (eg, SAE or AE or dose modification), then the results 
must be recorded in the CRF. The clinical laboratory parameters  that will be measured are de scribed in Appendix 2: Clinical 
laboratory tests ( Section  10.2). Decision trees for the mana gement of certain laboratory 
abnormalities by [CONTACT_208551] 6: Liver a nd Other Safety: Suggested Actions 
and Follow-up Assessments ( Section  10.6). 
For patient(s) who have consented to it, the samples that are archived, unused or left over after 
planned testing may be used for additional re search purposes (Appendix 17: Future Use of 
Samples, see Section  10.17. 
8.3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  
The definitions of an AE or SAE can be found in Appendix 3: Adverse Events: Definitions and 
Procedures for Recording, Evalua ting, Follow-up, and Reporting (Section  10.3). 
AE will be reported by [CONTACT_2299] (or, when  appropriate, by a caregiver, surrogate, or the 
participant's legally authorized representative). 
The Investigator and any qualified designees ar e responsible for detecting, documenting, and 
recording events that me et the definition of an AE or SAE and remain responsible for following 
Amended Clinical Trial Protocol [ADDRESS_248917]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 55 up AEs that are serious, considered related to th e IMP or study procedures, or that caused the 
participant to discontinue the IMP ( Section  7). 
8.3.[ADDRESS_248918] (AESI) is an AE (serious or nonserious) of scientific and 
medical concern specific to the Sponsor’s produc t or program, for which ongoing monitoring and 
immediate notification by [CONTACT_56481] e Sponsor is required. Such events may require 
further investigation in order to characterize and understand them. Adve rse events of special 
interest may be added, modified or rem oved during a study by [CONTACT_208552]. 
For these AESIs, the Sponsor will be informed  immediately (ie, within 24 hours), per SAE 
notification described in Section  8.3.2, even if not fulfilling a seriousness criterion, using the 
corresponding pages in the CRF (to be sent) or sc reens in the e-CRF.  If an SAE or any AESI of 
anaphylactic reactions or systemic allergic reactions that are relate d to IMP and require treatment, 
or severe injection site reactio ns lasting longer than 24 hours, o ccurs in a patient, blood samples 
should be collected for determination of functional dupi[INVESTIGATOR_24762], and ADA 
assessment at or near the onset  and completion of the occurrence of the event, if possible  
(see Section  8.5.3  for details). 
 Clinically symptomatic eosinophi lia (or eosinophilia associated  with clinical symptoms). 
 Anaphylactic reactions or systemic allergic re actions that are relate d to IMP and require 
treatment (see Appendix 15, Section  10.15). 
 Severe injection site reactions that last longer than 24 hours. 
 Any infection meeting at least one of the following criteria: 
- Any serious infection (SAE). 
- Requires parenteral (intravenous , intramuscular, subcutaneo us) antimicrobial therapy. 
- Requires oral antimicrobial ther apy for longer than 2 weeks. 
- Is a parasitic infection. 
- Is an opportunistic in fection (see Appendix 16, Section  10.16). 
Note:  antimicrobial therapy refers to antibiotic, antiviral, and antifungal agents 
 Any severe type of conjun ctivitis or blepharitis.  
 Keratitis. 
 Significant ALT elevation: 
- ALT >5 × the upper limit of normal (U LN) in patients with baseline ALT ≤2 × ULN, 
or 
- ALT >8 × ULN if baseline ALT >2 × ULN. 
 Pregnancy of a female subject entered in a study as well as pregnancy occurring in a 
female partner of a male subject entered in a study with IMP/NIMP. 
- Pregnancy o
ccurring in a female patient entered in the clinical trial or in a female 
partner of a male patient entered in the clinical trial. It will be qualified as an SAE only 
if it fulfills one of the seriousness criteria (see Appendix 3 [ Section  10.3]). 
- In the event of pregnancy in a female participant, IMP should be discontinued. 
Amended Clinical Trial Protocol [ADDRESS_248919]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 56 - Follow-up of the pregnancy in a female partic ipant or in a female partner of a male 
participant is mandatory until the outcome has been determined (see Appendix 4 
[Section  10.4]). 
- Abnormal pregnancy outcomes (eg, spontan eous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs. 
 Symptomatic overdose (serious or  nonserious) with IMP/NIMP. 
- An overdose (accidental or intentional) w ith the IMP is an event suspected by [CONTACT_208553]  11 days. The circumstances (ie, accidental 
or intentional) should be clea rly specified in the overdose form and symptoms, if any, 
entered on separate a dverse event forms. 
- An overdose (accidental or intentional) w ith any NIMP is an event suspected by [CONTACT_208554] a drug label, within the intended therapeutic 
interval. The circumstances (ie, accidental or intentional) should be clearly specified in 
the overdose form and symptoms, if any, entered on separa te adverse event forms. 
Asymptomatic overdose should also be reported on the overdose form. 
8.3.2 Time period and frequency for collecting AE and SAE information  
All AEs and SAEs will be collected from the si gning of the ICF until the follow-up visit at the 
time points specified in the SoA (Section  1.3), or up to recovery or stabilization of any AE to be 
followed-up as specified in this protocol, whichever comes last. 
All SAEs and AESI will be recorded and reported to the Sponsor or designee within 24 hours, as 
indicated in Appendix 3 ( Section  10.3). The Investigator will s ubmit any updated SAE data to the 
Sponsor within 24 hours of it being available. Investigators are not obligated to actively seek AE or SAE after conclusion of the study 
participation. However, if the Investigator learns  of any SAE, including a death, at any time after 
a participant has been discharged  from the study, and he/she consid ers the event to be reasonably 
related to the study intervention or  study participation, th e Investigator must promptly notify the 
Sponsor. 
The method of recording, evaluati ng, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE re ports are provided in Appendix 3 ( Section  10.3). 
8.3.3 Method of detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferre d method to inquire about AE 
occurrences. 
Amended Clinical Trial Protocol [ADDRESS_248920]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 57 8.3.4 Follow-up of AEs and SAEs  
After the initial AE/SAE report, the Investigator is required to proactively follow each participant 
at subsequent visits/contacts. At th e pre-specified study end-date, all SAEs,  and non-serious AEs 
of special interest (as defined in Section 8.3.1), will be followed until reso lution, stabilization, the 
event is otherwise explained, or the particip ant is lost to follow-up (as defined in Section 7.3). 
Further information on follow-up pro cedures is given in Appendix 3 ( Section  10.3). 
8.3.5 Regulatory reporting requirements for SAEs  
 Prompt notification by [CONTACT_208555] a SA E is essential so that legal 
obligations and ethical responsibil ities towards the safety of pa rticipants and the safety of 
a study intervention under clinic al investiga tion are met. 
 The Sponsor has a legal responsibility to not ify both the local re gulatory authority and 
other regulatory agencies about the safety  of a study intervention under clinical 
investigation. The Sponsor w ill comply with country-speci fic regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional Review 
Boards (IRB)/Independent Ethics Co mmittees (IEC), and Investigators. 
 Investigator safety reports mu st be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]Rs) according to local regu latory requirements and Sponsor policy and 
forwarded to Investigators as necessary. 
 Adverse events that are considered expected  will be specified in the reference safety 
information. 
 An Investigator who receives an Investigat or safety report describing a SAE or other 
specific safety information (eg, summary or li sting of SAEs) from th e Sponsor will review 
and then file it along with the Investigator’s Brochure and will not ify the IRB/IEC, if 
appropriate according to local requirements. 
8.3.6 Pregnancy  
See AESI ( Section  8.3.1). 
8.3.7 Adjudication Committee  
Adjudication will be performed by [CONTACT_208556], cardiovascular SAEs and respi[INVESTIGATOR_208470]. 
A confirmatory adjudication will occur for AE COPD exacerbations. Adjudicators will adjudicate 
these events in a consistent a nd unbiased manner throughout the study. 
The goal of the adjudication is to ensure that all events reported by [CONTACT_208557], using pre-specified criteria by a group inde pendent of the Sponsor . Adjudication Committee 
members will be blinded to treatment a llocation. Adjudication Committee members’ 
responsibilities and the process for data review are described in the AC Charter/Manual of 
Operation. 
Amended Clinical Trial Protocol [ADDRESS_248921]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 58 8.3.8 Disease-related events and/or disease-related outcomes not qualifying as AEs or 
SAEs  
In this study, some AEs are considered rela ted to the underlying condition. Specifically, for 
patients with COPD worsening of underlying condition is not cons idered an AE unless it meets 
serious criteria as de fined in Appendix 3 ( Section  10.3). 
8.3.[ADDRESS_248922] complaints / medical device incidents (including 
malfunctions)  
Any defect in the IMP/NIMP must be reported as soon as possible by [CONTACT_3433] e Investigator to the 
monitoring team that will co mplete a product comp laint form within required timelines. 
Appropriate information (eg, samples,  labels or documents like pi[INVESTIGATOR_208471]) related to 
product identification an d to the potential deficiencies may ne ed to be gathered. The Investigator 
will assess whether or not the quality issue has to  be reported together with an AE or SAE. 
8.4 TREATMENT OF OVERDOSE  
Symptomatic overdose is an AESI (defined in Section  8.3.1). No antidote is available for 
dupi[INVESTIGATOR_12458]. 
In the event of an overdose, the In vestigator/treati ng physician should: 
1. Contact [CONTACT_27465]. 
2. Closely monitor the participan t for any AE/SAE and laboratory abnormalities until study 
intervention can no longer be  detected systemically. 
3. Obtain a serum sample for PK analysis as soon as  possible from the date of the last dose of 
study intervention if requested by [CONTACT_208558] (determin ed on a case-by-case 
basis). 
4. Document the quantity of the excess dose as well as the duration of the overdose in the 
CRF. 
Decisions regarding dose interruptions or modifi cations will be made by [CONTACT_203790]. 
8.5 PHARMACOKINETICS  
8.5.1 Sampling time  
Blood samples will be collected for determina tion of functional dupi[INVESTIGATOR_181159]-dupi[INVESTIGATOR_208472] ( Section  1.3). Special procedures for collection, 
storage, and shippi[INVESTIGATOR_208473] e described in separate operationa l manuals. The date and time 
of collection should be recorded in the patient e-CRF. 
Amended Clinical Trial Protocol [ADDRESS_248923]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 59 8.5.2 Handling procedures  
Special procedures for collection, storage, and shippi[INVESTIGATOR_208474]. An overview of handling proce dure for samples used in the determination of 
systemic drug concentration and ADA is provided in Table 6 . 
Table 6 - Summary of handling procedures for dupi[INVESTIGATOR_208475]-dupi[INVESTIGATOR_181209] 5 mL 5 mL 
Anticoagulant None None 
Blood handling procedures See Operational Manual See Operational Manual 
Serum aliquot split 2 aliquots 2 aliquots 
Storage conditions <6 months:  below -20 °C 
<24 months: below -80 °C (preferred) <6 months:  below -20 °C 
<24 months: below -80 °C (preferred) 
Serum shipment condition In dry ice In dry ice 
8.5.3 Bioanalytic method  
Serum PK and ADA samples will be assayed us ing validated methods  as described in Table 7 . 
Table 7 - Summary of bioanalytical methods for dupi[INVESTIGATOR_181159]-dupi[INVESTIGATOR_208476]-dupi[INVESTIGATOR_208477]-chemiluminescence 
Site of bioanalysis Regeneron Regeneron 
ELISA=enzyme-linked immunosorbent assay. 
Drug concentration information that may unblind th e study will not be reported to investigative 
sites or blinded personnel unt il the study has been unblinded. 
Note: In case of a suspected SAE or any AESI event like anaphylactic reactions or systemic 
hypersensitivity that may be related to IMP and requi re treatment, or severe  and serious injection 
site reactions lasting more than  [ADDRESS_248924] be document ed and approved by [CONTACT_208559],  but will not constitute a protocol amendment. 
The IRB/IEC will be informed of any safety issues  that require alteration of the safety monitoring 
scheme or amendment of the ICF. 
Amended Clinical Trial Protocol [ADDRESS_248925]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 60 8.6 PHARMACODYNAMICS  
8.6.1 Pharmacodynamic variables/biomarkers  
 Pharmacodynamic response of selected biomarkers. 
- PARC. 
- Eotaxin-3. 
- FeNO (postbronchodilator). 
- Total IgE. 
- Fibrinogen. 
 Serum/plasma for archival purposes.  
For timing of PD sample collection refer to SoA ( Section  1.3). 
Assay methodologies are briefly su mmarized below. More detailed information on th e collection, 
handling, transport, and preser vation of samples (eg, min imum volumes required for blood 
collection and for aliquots  for each biomarker assay) will be  provided in a separate laboratory 
manual. 
Specific procedures for collection, storag e and shippi[INVESTIGATOR_208478] a lab manual. Whole blood biomarkers Blood eosinophil and neutrophil counts will be meas ured as part of the standard 5-part WBC 
differential cell count on  a hematology auto analyzer. Blood eosinophil and neutrophil counts will 
be measured at timepoints  additional to hematology ( Section  1.3). 
Plasma/serum biomarkers PARC will be assayed using a va lidated enzyme immunoassay. 
Fibrinogen assay: (development of immunoassay method ongoing). 
Eotaxin-[ADDRESS_248926] asma with a validated enzyme immunoassay. 
Total IgE will be measured w ith a quantitative method (eg, Phadia ImmunoCAP) approved for 
diagnostic testing. Exhaled nitric oxide FeNO will be analyzed using a NIOX instrument (Aerocrine AB, Solna, Sweden), or similar 
analyzer using a flow rate of 50 mL/s, and repor ted in parts per billion (ppb). This assessment 
should be done after pre-bronchodilator spi[INVESTIGATOR_208479]. 
Further details on the procedure for measuring exha led nitric oxide with NIOX will be provided in 
a separate instruction manual. 
Amended Clinical Trial Protocol [ADDRESS_248927]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 61 8.7 PHARMACOGENOMICS  
Pharmacogenetic/Pharmacogenomic testing is optional and volunt ary. Written informed consent 
must be obtained before sampling. 
For those patients who consent to the optiona l pharmacogenetic/pharmacogenomic sample 
collection section of the informed consent fo rm (ICF), blood samples fo r exploratory genetic 
analysis of DNA or RNA will be collected at  the study visit as specified in the SoA ( Section  1.3), 
and these samples will be stored for future anal ysis. Specific procedures for collection, storage 
and shippi[INVESTIGATOR_208480]/pharmacogenomic samples will be provided in a lab manual. 
For patient(s) who have consented to it, the samples that are archived, unused or left over after 
planned testing may be used for additional re search purposes (Appendix 17: Future use of 
samples, see Section  10.17). 
In the event of DNA extraction failure, a repl acement genetic blood sample may be requested 
from the participant. 
8.8 BIOMARKERS  
Pharmacodynamic and pharmacogenetic s biomarkers are described in Section  8.6.1 and 
Section  8.7, respectively. 
8.9 HEALTH CARE RESOURCE UTILIZATION  
A questionnaire of health care resource util ization (reliever medication, physician visit, 
hospi[INVESTIGATOR_059], emergency or urgent medical care facility visit, sick  leaves includi ng loss of usual 
activity days) will be collected by [CONTACT_208560]. 
Amended Clinical Trial Protocol [ADDRESS_248928]-2023 
Version number: [ADDRESS_248929] placebo on the primary 
endpoint of annualized rate of  moderate-to-severe COPD ex acerbations over the 52-week 
treatment period are as follows: 
 Null hypothesis: 𝑟ௗ௨௣௜௟௨௠௔௕𝑟௣௟௔௖௘௕௢ൗ ൌ1. 
 Alternative hypothesis: 𝑟ௗ௨௣௜௟௨௠௔௕𝑟௣௟௔௖௘௕௢ൗ ്1. 
Where 𝑟ௗ௨௣௜௟௨௠௔௕  and 𝑟௣௟௔௖௘௕௢  represent exacerbation rate in the dupi[INVESTIGATOR_197356], 
respectively. 
The statistical hypotheses used to test dup ilumab 300 mg q2w agains t placebo on the key 
secondary endpoint of pre-bronchodilator FEV1  from baseline to Week 12 are as follows: 
 Null hypothesis: 𝑐ௗ௨௣௜௟௨௠௔௕ ൌ𝑐௣௟௔௖௘௕௢ . 
 Alternative hypothesis: 𝑐ௗ௨௣௜௟௨௠௔௕ ്𝑐௣௟௔௖௘௕௢ . 
Where 𝑐ௗ௨௣௜௟௨௠௔௕  and 𝑐௣௟௔௖௘௕௢  represent change in  pre-bronchodilator FEV 1 in the dupi[INVESTIGATOR_208481], respectively. The statistical hypotheses to be tested on other key secondary endpoints, change in 
pre-bronchodilator FEV
1 from baseline to Week 12 and change  from baseline to Week 52 in the 
SGRQ total score compared to placebo, can be speci fied similarly as those on the change in FEV 1 
at Week 12. For the proportion of patients with SGRQ improvement ≥[ADDRESS_248930] acebo annualized rate of  exace rbations being 1.5, an average 
treatment duration of 0.95 year (t o account for an average of 5% of the planned treatment period 
with missing data), and a ra ndomization ratio of 1:1 to th e two treatment arms, with  
924 randomized patients (462 for each treatment ar m), the study will have 90% power to detect a 
25% relative risk reduction (ie, annualized  rate of 1.125 for the dupi[INVESTIGATOR_24769]) in the 
annualized rate of moderate or severe COPD exacerbations at th e 2-tailed significance level of 
α =0.05. With the addition of an interim analysis , the final alpha may be reduced to 0.049, which 
maintains approximately 90% power (see Section  9.5 for further details). 
Patients will be randomized using a 1:1 randomization ratio to dupi[INVESTIGATOR_12458] 300 mg q2w or placebo. Randomization will be stratified by [CONTACT_1606], ICS dos e (high dose ICS [yes/no]) at baseline, and 
Amended Clinical Trial Protocol [ADDRESS_248931]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 63 smoking status at screening (current smokers or not). As an exam ple, the adult high dose of ICS 
for fluticasone propi[INVESTIGATOR_28321] >500 mcg (DPI [INVESTIGATOR_208444]) or 401-800 mcg (HFA) for Japanese 
population (please refer to Section  10.[ADDRESS_248932] common ICS). Alerts will be built into the 
IVRS/IWRS to limit enrolling pati ents who are current smokers (a s defined by [CONTACT_208561]) to less than or e qual to 30% or 278 patients out of  the total enrolled patients. 
9.3 POPULATIONS FOR ANALYSES  
For purposes of analysis, the fo llowing populations are defined ( Table 8 ): 
Table 8 - Populations for analyses  
Population Description 
Screened All patients who signed the ICF. 
Randomized The randomized population in cludes all patients with a treatment kit number allocated and recorded 
in the IRT database, and regardless of whether the treatment kit was used or not. 
Patients treated without being randomized will not be considered randomized and will not be 
included in any efficacy population, but will be included in the safety population. 
Intent-to-treat (ITT) All randomized patients analyzed accordi ng to the treatment group allocated by [CONTACT_17628]. 
Efficacy The ITT population. 
Safety The safety population includes all patients who actually received at least one dose or partial of a 
dose of the IMP, analyzed according to the treatment actually received. 
Randomized patients for whom it is  unclear whether they took th e study medication will be included 
in the safety population as randomized.  
For patients on dupi[INVESTIGATOR_208482], the actual 
treatment group allocation for as-treated analysis will be the dupi[INVESTIGATOR_24769]. 
The pharmacodynamic (PD) analyses will be performed on the safety population. 
Pharmacokinetic (PK) The PK population includes all patients in the safety population with at least one non-missing result for 
functional dupi[INVESTIGATOR_208483]. Patients will be 
analyzed according to the treatment actually received. 
Antidrug antibody (ADA) ADA population includes all patients in the safety population who have at least one non-missing ADA 
result after first dose of the study treatment.  Pati ents will be analyzed according to  the treatment actually 
received. 
 
9.4 STATISTICAL ANALYSES  
The statistical analysis plan will be developed an d finalized before database lock for the interim 
analysis (see Section  9.5) and will describe the participant populations to be included in the 
analyses, and procedures for acc ounting for missing, unused, and spur ious data. This section is a 
summary of the planned statis tical analyses of the prim ary and secondary endpoints. 
Amended Clinical Trial Protocol [ADDRESS_248933]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 64 9.4.1 Efficacy analyses  
Table 9 - Efficacy analyses  
Endpoint Statistical Analysis Methods 
Primary 
Annualized rate of moderate 
and severe COPD exacerbations over 52-week treatment period. The annualized rate of moderate and severe COPD exacerbation events will be analyzed 
using a negative binomial regression model. T he model will include the total number of 
events occurring during the 52-week treatment period as the response variable, with the 
treatment group, region (pooled country), ICS dos e (high dose ICS [yes/no]), smoking status 
at screening (current smokers or not), base line disease severity (as % predicted post-
bronchodilator FEV
1), and number of moderate or severe COPD exacerbation events within 
one year prior to the study ( ≤2, 3, or ≥4) as covariates. Log-transformed observation 
duration will be used as offset variable. The estimated annualized event rate for each 
treatment group and its two-sided 95% confidence intervals will be derived. The event rate 
ratio of the dupi[INVESTIGATOR_208484], its two-sided 95% confidence interval and 
p-value will be provided. Patients who permanent ly discontinue the study treatment will be 
encouraged to complete the study as planned and the additional off-treatment exacerbation events up to Week [ADDRESS_248934] to age, gender, 
region, race, weight, BMI, smoking status, ICS dose (high dose ICS [yes/no]), disease 
severity (as % predicted post-bronchodilator FEV 1), number of moderate-or-severe COPD 
exacerbation events within one year prio r to the study, pre-bronchodilator FEV 1, and other 
factors that will be specified in SAP.  
Baseline biomarker-by-treatment interacti on on the efficacy endpoints will be analyzed to 
evaluate the potential predictive effect of bas eline biomarkers on the treatment response. 
Key secondary 
Change in pre-bronchodilator 
FEV [ADDRESS_248935] model with repeated measures  (MMRM). The model will include change from 
baseline in FEV 1 values up to Week 12 as response variables, and factors for treatment 
group, age, sex, baseline height, region ( pooled country), ICS dose (high dose ICS 
[yes/no]), smoking status at screening (curr ent smokers or not), visit, treatment-by-visit 
interaction, baseline pre-bronchodilator FEV 1, and FEV [ADDRESS_248936] square (LS) mean of the change in pre-bronchodilator FEV
1 of each treatment group, difference in the LS mean changes 
between the dupi[INVESTIGATOR_125316], the co rresponding 95% CI of the differences 
and p-values will be provided. For patient s who discontinued the study treatment, 
off-treatment FEV [ADDRESS_248937] 
as change in pre-bronchodilator FEV
1 at Week 52 except that the MMRM model will include 
the following covariates: treatment group, r egion (pooled country), IC S dose (high dose ICS 
[yes/no]), smoking status at screening (curr ent smokers or not), visit, treatment-by-visit 
interaction, baseline SGRQ total score, and SGRQ baseline-by-visit interaction. 
Amended Clinical Trial Protocol [ADDRESS_248938]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 65 Endpoint Statistical Analysis Methods 
Proportion of patients with 
SGRQ improvement  ≥4 points at Week 52. The proportion of patients with SGRQ improvement ≥4 points at Week 52 will be analyzed 
using a logistic regression model. The model  will include treatment group, region (pooled 
country), ICS dose (high dose ICS [yes/no]), smoking status at screening (current smokers 
or not), and baseline SGRQ total score as covariates. Patients with missing SGRQ total score at Week 52 will be considered as non-responders.
 
Other secondary 
Change in pre-bronchodilator 
FEV 1 from baseline to Weeks 
other than 12 & 52. The change in pre-bronchodilator FEV [ADDRESS_248939]-bronchodilator 
FEV 1, change in forced 
expi[INVESTIGATOR_10229] (FEF) 25-75%. The change in the spi[INVESTIGATOR_208485]-bronchodilator FEV1 except that the corresponding baseline of the parameter 
will replace baseline pre-bronchodilator FEV [ADDRESS_248940] event as the dependent 
variable, and treatment group, region (pooled count ry), ICS dose (high dose ICS [yes/no]), 
smoking status at screening (current smoker s or not), baseline disease severity (as % 
predicted post-bronchodilator FEV1), and number of moderate or severe COPD 
exacerbation events within one year prior to the study ( ≤2, 3, or ≥4) as covariates. 
The Kaplan-Meier method will be used to deriv e the probabilities that a patient would 
experience event up to specific timepoints for each treatment group. 
Annualized rate of severe COPD exacerbations over the 
52-week treatment period. The annualized event rate of severe COPD ex acerbations will be analyzed in the same way 
as the primary analysis for the annualized rate  of moderate or severe COPD exacerbation 
events.
 
Exploratory Analysis of Exploratory endpoints w ill be described in the SAP finalized before database 
lock for the interim analysis. 
 If the primary endpoint is statisti cally significant at th e interim analysis th en for the continuous 
and proportion type endpoints at Week 52, only participants who have the opportunity to reach 
Week 52 assessments at the time of the interim an alysis cut-off date (ie,  completed the Week [ADDRESS_248941] completed had they not discontinued) will contri bute to the inferential 
analyses. 
[IP_ADDRESS] Multiplicity considerations  
Multiplicity is considered for performing an inte rim analysis and for testing multiple endpoints. 
The overall Type-I error rate will be controlled at the two-sided 0.05 level. 
An interim analysis will be performed using the Kim-DeMets spending function ( 26) when the 
information fraction for the primary endpoint is ≥0.92 (see Section  9.5). A hierarchical testing 
procedure will be used for the testing primary, key secondary and other endpoints. The annualized 
rate of moderate and severe COPD exacerbations  over the 52-week treatment period will be first 
tested with an alpha as determined in Table 12. Only upon rejection of the null hypothesis for the annualized rate of moderate and severe COPD  exacerbations can the key secondary endpoint, 
change in pre-bronchodilator FEV
[ADDRESS_248942]-2023 
Version number: [ADDRESS_248943] available 
value before randomization. The treatment emergent  adverse event (TEAE) period is defined as 
the time between the first administration of stud y medication to the last administration of the  
IMP +98 days. 
Table 10 - Safety analyses  
Endpoint Statistical Analysis Methods 
AE, SAE, AE 
leading to death, AE leading to 
permanent 
treatment 
discontinuation. Adverse event incidence tables will present by [CONTACT_9313] (SOC) (sorted by [CONTACT_208562]), high-level group term (HLGT), high level term (HLT) and preferred term (PT) sorted in alphabetical 
order for each treatment group, the number (n) and per centage (%) of patients experiencing an AE. Multiple 
occurrences of the same event in the same patient will be counted only once in the tables within a treatment phase. The denominator for computation of percentages  is the safety population within each treatment 
group. 
Proportion of patients with at least one TEAE, trea tment emergent SAE, TEAE leading to death, and TEAE 
leading to permanent treatment discontinuation will be t abulated by [CONTACT_1570]. In addition TEAEs will 
be described according to maximum intensity and relation to the study drug. AEs that occur outside the 
treatment-emergent period will be summarized separately. 
Major 
Cardiovascular Adverse 
Events (MACE) The number and percentage (%) of patients with any tr eatment-emergent event selected for adjudication will 
be summarized by [CONTACT_183008]. 
All events submitted for adjudication will be listed, including the final adjudicated result. The number and percentage (%) of patients experienci ng a treatment-emergent adjudicated event will be 
summarized within each treatment group. The risk difference (asymptotic 95% CI with conti nuity correction) will be computed for the dupi[INVESTIGATOR_208486]. Kaplan-Meier plots to depi[INVESTIGATOR_163368] c ourse of onset over time  will also be provided. 
AESI and other 
AE groupi[INVESTIGATOR_208487]. For each type 
of AESI, the following analysis will be generated. 
 A summary of the number (%) of patients with 
- Any TEAE. 
- Any SAE (regardless of treatment-emergent status). 
- Any treatment-emergent SAE. 
- Any AE leading to death. 
- Any TEAE leading to death. 
- Any TEAE leading permanent treatment discontinuation. 
- Any TEAE related to IMP reported by [CONTACT_10670]. 
- Number of patients with the TEAE per 100 patient-years. 
- Any TEAE by [CONTACT_11196], corr ective treatment, and final outcome. 
 Kaplan-Meier (K-M) estimates of probability of havi ng at least one TEAE at specific time points, 
and K-M curve to depi[INVESTIGATOR_208488]. 
The method to identify AESIs and other AE gr oupi[INVESTIGATOR_208489]. 
Death The following deaths summaries will be generated: 
 Number (%) of patients who died by [CONTACT_208563] (TEAE, on-study) summa rized on the safety 
population by [CONTACT_82153]. 
 Death in nonrandomized patients or randomized and not treated patients. 
Treatment-emergent AE leading to death (death as an out come on the AE eCRF page as reported by [CONTACT_3786]) by [CONTACT_148274], HLGT, HLT, and PT showing number (%) of patients sorted by [CONTACT_208564], HLT, and PT. 
Amended Clinical Trial Protocol [ADDRESS_248944]-2023 
Version number: [ADDRESS_248945] deviation, median, Q1, Q3, minimum, and maximum. 
The following definitions will be a pplied to laboratory parameters. 
 The potentially clinically significant abnormality (PCSA) values  are defined as abnormal values 
considered medically important by [CONTACT_1034] a ccording to predefined criteria/thresholds based 
on literature review and defined by [CONTACT_941] S ponsor for clinical laboratory tests. 
 PCSA criteria will determine which patients had at least [ADDRESS_248946] to the baseline status will be 
provided. 
9.4.3  Other analyses   
PK, pharmacodynamic, and biomarker exploratory an alyses will be described in the statistical 
analysis plan finalized before database lo ck. The population PK analysis and pharmacodynamic 
analyses will be presented separately from the main clinical  study report (CSR). 
Table 11  provides a summary of th e planned statistical analys es of the other endpoints. 
Table 11 - Other analyses  
Endpoint Statistical Analysis Methods 
PK Serum concentrations of SAR231893 (REGN668) will be su mmarized for the dupi[INVESTIGATOR_208490], SD, standard error of t he mean (SEM), coefficient of variation (CV), minimum, 
median and maximum per sampling time.  
ADA The incidence of treatment-emergent ADA response  for SAR231893 (REGN668) will be provided by [CONTACT_98540], including characterization of the response with  titers and neutralizing antibody status. Association of 
ADA with impact on drug concentration profile, effica cy and safety may be explored. ADA analysis will be 
detailed in the SAP. 
PD For all PD parameters, raw data at each visit, absolute changes from baseline, and percent changes from 
baseline will be summarized in descriptive st atistics by [CONTACT_11571].  
Summary plots (mean ± standard error of the mean) on raw data, absolute changes from baseline and percent 
changes from baseline will be provided by [CONTACT_6660]. 
 
Data collected regarding the impact of the COVID-19 or other pandemics on the participants will be summarized (eg, discontinuation due to CO VID-19). Any additional analyses and methods 
required to investigate the impact of COVID-19 or other events re quiring public health emergency 
on the efficacy (eg, missing data due to COVID-19) and safety will be detailed in the SAP. 
Amended Clinical Trial Protocol [ADDRESS_248947]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 68 9.5 INTERIM ANALYSES   
An interim analysis is planned when the information fraction is ≥0.[ADDRESS_248948] complete follow-up for the key secondary 
endpoint of change from baseline in FEV 1 at Week 12. The purpose of th is interim analysis is to 
potentially demonstrate efficacy when ≥92% of the information frac tion for the primary endpoint 
is available, but prior to a ll patients completing the 52-week treatment period, as COPD is a 
disease with a high unmet medical need.  
To control the overall type I error at α=0.05, the Kim-DeMets approach (26) will be used with the 
power parameter rho (ρ ) determined based on the information fraction observed at the time of the 
interim analysis and to maintain an α=0.049 at the final analysis ( Table 12 ). 
Table 12 - Kim-DeMets alpha spending functi on to control the overall alpha at 0.05  
Information fraction Rho (ρ) α at interim analysis α at final analysis 
0.92 to <0.93 12 0.018 0.049 
0.93 to <0.94 12 0.020 0.049 
0.94 to <0.95 13 0.022 0.049 
0.95 to <0.96 14 0.024 0.049 
0.96 to <0.97 15 0.027 0.049 
If the primary endpoint does not demonstrate efficacy  at this interim analysis then the study will 
remain blinded and the primary endpoint will be retested at the final analysis with an α=0.049. 
If the primary endpoint demonstrates efficacy at this interim analysis then the rest of the 
multiplicity-controlled endpoints will be tested with α=0.05. Further details will be provided in 
the study SAP. This interim analysis will be performed by [CONTACT_208565]. The DMC will review the unblinded result 
of the primary endpoint and will co mmunicate if the criterion for effi cacy is met as prespecified in 
the SAP. The DMC is established and will continue the regular review of unblinded safety data as 
described in the DMC charter. In the event that statistical sign ificance is demonstrated on the 
primary endpoint the additional analyses will be  performed by [CONTACT_208566]. To 
maintain study integrity with respect to the subs equent visits, follow-up a nd analyses after this 
interim analysis, a disseminati on plan will be written. This plan will clearly identify two 
independent study teams (blinded team and unbli nded team) and provide further details on the 
unblinding plan. People involved in the conduct of the study (patients, Investigators, Site Staff, 
and the blinded Study and Project Team) will have no access to unblinded patient level data, 
individual patient treatment codes, or unblinded tables or figures (see th e Dissemination plan for 
details). 
If efficacy at the interim analysis is not demonstrated the data base lock for primary analysis is 
planned based on the date when the last patien t completes the Week [ADDRESS_248949]-2023 
Version number: [ADDRESS_248950]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 70 10 SUPPORTING DOCUMENTA TION AND OPERATIONAL 
CONSIDERATIONS  
10.1 APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT 
CONSIDERATIONS  
10.1.1 Regulatory and Ethical Considerations  
 This study will be conducted in accordance w ith the protocol and with the following: 
- Consensus ethical principles derived fro m international guide lines including the 
Declaration of Helsinki and the applicable amendments and Council for International 
Organizations of Medical Sciences (CIO MS) International Ethical Guidelines. 
- Applicable ICH Good Clinical  Practice (GCP) Guidelines. 
- Applicable laws and regulations. 
 The protocol, protocol amendments, ICF, Investigator Br ochure, and other relevant 
documents (eg, advertisements) must be submitted, as required by [CONTACT_56528], to an 
IRB/IEC and to the Health Authorities (competent regulato ry authority) by [CONTACT_208567], where further required by [CONTACT_208568], reviewed and approved 
by [CONTACT_1201]/IEC and Health Authorit ies before the study is initiated. 
 Any amendments to the protocol  will require IRB/ IEC approval before implementation of 
changes made to the study de sign, except for changes necessar y to eliminate an immediate 
hazard to study participants. 
 The Investigator will be res ponsible for the following: 
- Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC. 
- Notifying the IRB/IEC of SAEs or other sign ificant safety findings as required by 
[CONTACT_1744]/IEC procedures. 
- Providing oversight of the conduct of th e study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 
for clinical studies (if ap plicable), and all other applicable local regulations. 
10.1.2 Informed consent process  
 The Investigator or his/her representative will explain the nature  of the study to the 
participant or his/her legally authorized repr esentative and answer all questions regarding 
the study. 
 Participants must be informed that their pa rticipation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of  
[ADDRESS_248951] (HIPAA) requirements, where applicable, and the IRB/IEC or study center. 
Amended Clinical Trial Protocol [ADDRESS_248952]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 71  The medical record must include a statement that written informed  consent was obtained 
before the participant was enrolled in th e study and the date the written consent was 
obtained. The authorized person obtaining the in formed consent must also sign the ICF. 
 Participants must be re-consented to the most  current version of th e ICF(s) during their 
participation in the study. 
 A copy of the ICF(s) must be provided to the participant or the participant’s legally 
authorized representative. 
10.1.3 Data protection  
 All personal data collected rela ted to participants, Investigators, or any person involved in 
the study, which may be included in the Spons or’s databases, shall be treated in 
compliance with all applicable laws and re gulations including th e GDPR (Global Data 
Protection Regulation). Data co llected must be adequate, re levant and not excessive, in 
relation to the purposes for which they are collected. Each category of data must be 
properly justified and in line with the study objective. 
 Participant race and ethnicity will be collected in this study because these data are required 
by [CONTACT_17513] (eg, on African Americ an population for the FDA or on Japanese 
population for the PMDA in Japan). 
 Participants will be assigned a unique identifi er by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant 
names or any information which would make the participant identifiable will not be 
transferred. 
 The participant must be informed that his/her personal study-related data will be used by [CONTACT_208569]. The level of disclosure must also 
be explained to the participant. 
 The participant must be informed that hi s/her medical records may be examined by 
[CONTACT_198685], by [CONTACT_6667]/IEC members, a nd by [CONTACT_163574]. 
 When archiving or processing personal data pe rtaining to the Investig ator and/or to the 
participants, the Sponsor sha ll take all appropriate measur es to safeguard and prevent 
access to this data by [CONTACT_13159]. 
10.1.4 Committees structure  
Study committees 
The study data will be reviewed by a DMC and adjudication committee. 
[IP_ADDRESS] Data Monitoring Committee (DMC)  
A DMC, independent from sponsor will be established for this study. This committee is 
comprised of externally-based individuals with expertise in the diseases under study, biostatistics, 
or clinical research. The primary responsibilities of the DMC are to review and evaluate the safety 
Amended Clinical Trial Protocol [ADDRESS_248953]-2023 
Version number: [ADDRESS_248954] of the clinical tria l to the Sponsor. 
The DMC procedures and safety and efficacy data  to be reviewed by [CONTACT_208570]. In the above capacities, the DMC is advisory to the Sponsor. The Sponsor is 
responsible for promptly revi ewing and for taking into ac count in a timely manner the 
recommendations of the DMC in terms of trial c ontinuation with or with out alterations or of 
potential trial termination. 
[IP_ADDRESS] Adjudication committee  
Adjudication will be performed by [CONTACT_208556], cardiovascular SAEs and respi[INVESTIGATOR_208470]. 
A confirmatory adjudication will occur for AE COPD exacerbations. Adjudicators will adjudicate 
these events in a consistent a nd unbiased manner throughout the study. 
The goal of the adjudication is to ensure that all events reported by [CONTACT_208557], 
using pre-specified criteria by a group inde pendent of the Sponsor . Adjudication Committee 
members will be blinded to treatment a llocation. Adjudication Committee members’ 
responsibilities and the process for data review are described in the AC Charter/Manual of 
Operation.  
10.1.5 Dissemination of clinical study data  
[COMPANY_011] shares information about clinical trials an d results on publically accessible websites, based 
on company commitments, international and local legal and regulatory re quirements, and other 
clinical trial disclosure commitments establis hed by [CONTACT_208571] i ndustry associations. 
These websites include clinicaltria ls.gov, EU clinicaltrialr egister (eu.ctr), and sanofi.com, as well 
as some national registries. 
In addition, results from clinical trials in patients are required to  be submitted to peer-reviewed 
journals following intern al company review for accuracy, fa ir balance and intellectual property. 
For those journals that request sharing of the analyzable data sets that are reported in the 
publication, interested researchers are directed to sub mit their request to vivli.org. 
Individual participant data and s upporting clinical documents are av ailable for request at vivli.org. 
While making information available we continue to protect the pr ivacy of participants in our 
clinical trials. Details on data  sharing criteria and process fo r requesting access can be found at 
this web address: vivli.org. 
10.1.6 Data quality assurance  
 All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the Sponsor or desi gnee electronically (eg, laboratory data). 
The Investigator is responsibl e for verifying that data entr ies are accurate and correct by 
[CONTACT_208572]. 
Amended Clinical Trial Protocol [ADDRESS_248955]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 73  The Investigator must maintain accurate do cumentation (source da ta) that supports the 
information entered in the CRF. 
 Monitoring details describing strategy (eg, risk-based initiatives in operations and quality 
such as Risk Management and Mitigation Strategies and Analytical Risk-Based 
Monitoring), methods, responsibilities a nd requirements, including handling of 
noncompliance issues and monitoring techniques (central, remo te, or on-site monitoring) 
are provided in separate study documents. 
 The Investigator must perm it study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents. 
 The Sponsor or designee is res ponsible for the data manageme nt of this study including 
quality checking of the data. 
 Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_78584] e accurate, complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with  the currently approved protocol and any 
other study agreements, ICH GCP, and a ll applicable regulat ory requirements. 
 Records and documents, including signed ICFs , pertaining to the c onduct of this study 
must be retained by [CONTACT_208573] 25 years after th e signature [CONTACT_208582] l policies require a longer retention period. 
No records may be destroyed during the rete ntion period without th e written approval of 
the Sponsor. No records may be transferred to  another location or party without written 
notification to the Sponsor. 
10.1.7 Source documents  
 Source documents provide evidence for the exis tence of the participant and substantiate 
the integrity of the data collected. Source docum ents are filed at the Investigator’s site. 
 Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent  with the source documents or  the discrepancies must be 
explained. The Investigator may need to reque st previous medical records or transfer 
records, depending on the study. Also, current  medical records must be available. 
 Definition of what constitutes source data  can be found in the Study Reference Manual. 
10.1.[ADDRESS_248956]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 74 Reasons for study termina tion by [CONTACT_1034], as well as reasons  for the early closure of a study 
site by [CONTACT_125491]: 
 For study termination: 
- Information on the product leads to d oubt as to the benefit/risk ratio. 
- Discontinuation of further study intervention development. 
 For site termination: - Failure of the Investigator to comply w ith the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor’s procedures, or GCP guidelines. 
- Inadequate or no recruitment (evaluated  after a reasonable amount of time) of 
participants by [CONTACT_737]. 
- Total number of participants in cluded earlier than expected. 
10.1.9 Publication policy  
 The results of this study may be published or presented at scientific  meetings. If this is 
foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor 
before submission. This allows the Sponsor to protect proprietary  information and to 
provide comments. 
 The Sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethica l practice, the Sponsor  will generally support 
publication of multicenter studies only in their entirety and not as indi vidual site data. In 
this case, a coordinating Investigator [INVESTIGATOR_12992]. 
 Authorship will be determined by [CONTACT_14346]. 
10.2 APPENDIX 2: CLINICAL LABORATORY TESTS  
 The tests detailed in Table 13  will be performed by [CONTACT_2237]. 
 Local laboratory results are only required in the event that the central laboratory results are 
not available in time for either study in tervention administration and/or response 
evaluation. If a local sample is required, it is im portant that the sample  for central analysis 
is obtained at the same time. A dditionally, if the local laborat ory results are used to make 
either a study intervention decision or respons e evaluation, the results must be entered into 
the CRF. 
 Protocol-specific requirements for inclusion or exclusion of participants are detailed in 
Section  5 of the protocol. 
 Additional tests may be performed at any time  during the study as determined necessary 
by [CONTACT_208574]. 
Amended Clinical Trial Protocol [ADDRESS_248957]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 75 Table 13 - Protocol-required safety laboratory assessments  
Laboratory 
assessments Parameters 
Hematology To include hemoglobin, hematocrit, platelet coun t, total white blood cell count with five-part differential 
count and total red blood cell count. 
Clinical chemistry To include creatinine, blood urea nitrogen, glucose, uric acid, total choleste rol, total protein, albumin, total 
bilirubin (in case of values above the normal r ange, differentiation in conjugated and non-conjugated 
bilirubin), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, lactate 
dehydrogenase, electrolytes (sodium, potassium, ch loride), bicarbonate, and creatine phosphokinase. 
Routine urinalysis To include urine dipstick analysis includi ng specific gravity, pH, glucose, ketones, blood, protein, nitrite, 
leukocyte esterase, urobilinogen and bilirubin (by [CONTACT_5230]).   If any assessment on the dipstick is abnormal, 
a urine sample should be sent to the central laborator y for testing. If positive for proteins, microscopic 
analysis is performed by [CONTACT_12115]. 
Other tests Clinical laboratory testing at Screening Visi t 1 will include hepatitis screen covering hepatitis B surface 
antigen (HBs Ag), hepatitis B surfac e antibody (HBs Ab), hepatitis B core antibody (HBc Ab), hepatitis C 
virus antibodies (HCV Ab), Human Immunodeficiency Vi rus (HIV) screen (Anti-HIV-1 and HIV-2 antibodies) 
and anti-nuclear antibody (ANA). In case of result s showing HBs Ag (negative), HBs Ab (negative) and 
HBc Ab (positive), an HBV DNA testing may be performed prior to randomization to rule out a false 
positivity if the Investigator believes the patient is a false positive, or to clarify the serological status if the Investigator finds it unclear to interpret in absence of  known HBV infection. In case of results showing HCV 
Ab (positive), an HCV RNA testing may be performed to rule out a false positivity, if the Investigator 
believes the patient is a false positive. 
Note: Anti-ds DNA antibody will be tested if ANA is positive ( ≥1:160 titer). 
Investigators must document their revi ew of each laboratory safety report. 
Laboratory/analyte results that c ould unblind the study will not be re ported to investigative sites 
or other blinded personnel until the study has been unblinded. 
10.3 APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING  
DEFINITION OF AE  
AE definition 
 An AE is any untoward medical occurrence in  a patient or clini cal study participant, 
temporally associated with the use of study intervention, whether or not  considered related 
to the study intervention. 
 NOTE: An AE can therefore be any unfa vorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study intervention. 
Events meeting the AE definition 
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (e g, ECG, radiological scans, vital signs measurements), 
including those that worsen fro m baseline, considered clinical ly significant in the medical 
and scientific judgment of the Investigator (ie, not relate d to progression of underlying 
disease). 
Amended Clinical Trial Protocol [ADDRESS_248958]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 76  Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or  intensity of the condition. 
 New conditions detected or diagnosed after st udy intervention admin istration even though 
it may have been present be fore the start of the study. 
 Signs, symptoms, or the c linical sequelae of a susp ected drug-drug interaction. 
 Signs, symptoms, or the clin ical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. 
 "Lack of efficacy" or "failure of expected  pharmacological action" per se will not be 
reported as an AE or SAE. Such instances wi ll be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinic al sequelae resulting fro m lack of efficacy 
will be reported as AE or SAE if they fulfil the definition of an AE or SAE. 
 The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be 
reported as AE or SAE if they fulfil the defi nition of an AE or SAE. Also, "lack of 
efficacy" or "failure of expect ed pharmacological action" also constitutes an AE or SAE. 
Events NOT meeting the AE definition 
 AECOPD unless it meets the criteria for SAE. 
 Any clinically signi ficant abnormal laboratory findings  or other abnormal safety 
assessments which are associated with th e underlying disease, unless judged by [CONTACT_13142]’s condition. 
 The disease/disorder being studied or expe cted progression, signs, or symptoms of the 
disease/disorder being studied, unless more se vere than expected for the participant’s 
condition. 
 Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE. 
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]). 
 Anticipated day-to-day fluctuations of pre-ex isting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
DEFINITION OF SAE 
If an event is not an AE per defini tion above, then it cannot be an SAE. 
A SAE is defined as any untoward me dical occurrence that, at any dose: 
a) Results in death. 
b) Is life-threatening. 
The term 'life-threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of deat h at the time of the event. It does not refer to an event, 
which hypothetically might have cause d death, if it were more severe. 
Amended Clinical Trial Protocol [ADDRESS_248959]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 77 c) Requires inpatient hospi[INVESTIGATOR_1081]. 
In general, hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight  stay) at the hospi[INVESTIGATOR_12332]/or treatment that would not have been  appropriate in the physician’s office or 
outpatient setting. Complicati ons that occur during hosp italization are AEs. If a 
complication prolongs hospi[INVESTIGATOR_208491], the event is 
serious. When in doubt as to whether “hospi [INVESTIGATOR_059]” occurred or was necessary, the 
AE should be considered serious. 
Hospi[INVESTIGATOR_5187] a pr e-existing condition that did not worsen 
from baseline is not considered an AE. 
d) Results in persistent disability/incapacity. 
- The term disability means a substantial di sruption of a person’s ability to conduct 
normal life functions. 
- This definition is not intended to include experiences of relati vely minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, spra ined ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption. 
e) Is a congenital anomaly/birth defect. 
f) Other situations: 
- Medical or scientific judgment should  be exercised in deciding whether SAE 
reporting is appropriate in ot her situations such as important medical events that 
may not be immediately life- threatening or result in death or hospi[INVESTIGATOR_208492]. These events 
should usually be considered serious.  
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic  bronchospasm, blood 
dyscrasias or convulsions that do not result  in hospi[INVESTIGATOR_059], or development of 
drug dependency or drug abuse. 
RECORDING AND FOLLOW-UP OF AE AND/OR SAE 
AE and SAE recording 
 When an AE/SAE occurs, it is the responsib ility of the Investigator to review all
 
documentation (eg, hospi[INVESTIGATOR_1088], la boratory reports, and diagnostics reports) 
related to the event. 
 The Investigator will then record all re levant AE/SAE information in the CRF. 
 It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_208493]’s medical 
records to the Sponsor’s representative in lieu of comple tion of the AE/SAE CRF page. 
 There may be instances when copi[INVESTIGATOR_208494]’s representative. In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_12997]’s representative. 
Amended Clinical Trial Protocol [ADDRESS_248960]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 78  The Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/sympt oms) will be documen ted as the AE/SAE.  
Assessment of intensity 
The Investigator will make an assessment of in tensity for each AE and SAE reported during the 
study and assign it to 1 of the following categories: 
 Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort and 
not interfering with everyday activities. 
 Moderate: An event that causes sufficient disc omfort and interferes with normal everyday 
activities. 
 Severe: An event that prevents normal everyda y activities. An AE that is assessed as 
severe should not be confused with a SAE. Severe is a category utilized for rating the 
intensity of an event; and both AEs a nd SAEs can be assessed as severe. 
An event is defined as ‘serious’ when it meets at  least 1 of the predefin ed outcomes as described 
in the definition of an SAE, NOT  when it is rated as severe. 
Assessment of causality 
 The Investigator is obligated  to assess the relationship between study intervention and 
each occurrence of each AE/SAE. 
 A "reasonable possibility" of a relationship conv eys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a re lationship cannot be ruled out. 
 The Investigator will use clinical judg ment to determine the relationship. 
 Alternative causes, such as underlying disease(s), concomita nt therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated. 
 The Investigator will also consult the I nvestigator’s Brochure (IB) and/or Product 
Information, for marketed pr oducts, in his/her assessment. 
 For each AE/SAE, the Investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provi ded an assessment of causality. 
 There may be situations in which an SAE has occurred and the Investigator has minimal 
information to include in th e initial report to the Sponsor’s representative. However, it is 
very important that the Investigator alw ays make an assessment of causality for 
every event before the initial transmissi on of the SAE data to the Sponsor’s 
representative. 
 The Investigator may change hi s/her opi[INVESTIGATOR_9242]-up information 
and send a SAE follow-up report with the updated causality assessment. 
 The causality assessment is one of the criteria  used when determining regulatory reporting 
requirements. 
Amended Clinical Trial Protocol [ADDRESS_248961]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 79 Follow-up of AEs and SAEs 
 The Investigator is obligated  to perform or arrange for the conduct of supplemental 
measurements and/or evaluations  as medically indicated or as  requested by [CONTACT_1034]’s 
representative to elucidate the nature and/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals. 
 New or updated information wi ll be recorded in the originally co mpleted CRF. 
The Investigator will submit any updated SAE da ta to the Sponsor/Sponsor’s representative 
within 24 hours of receip t of the information. 
REPORTING OF SAES 
SAE reporting to the Sponsor’s representative  via an electronic data collection tool 
 The primary mechanism for report ing an SAE to the Sponsor’s representative will be the 
electronic data collection tool. 
 If the electronic system is unavailable for mo re than 24 hours, then the site will use the 
paper SAE data collection tool (see next section). 
 The site will enter the SAE data  into the electronic system as  soon as it becomes available. 
 After the study is completed at a given site, th e electronic data collecti on tool will be taken 
off-line to prevent the entry of new data or changes to existing data. 
 If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electr onic data collection tool has been taken 
off-line, then the site can report this informat ion on a paper SAE form (see next section) or 
to the Sponsor’s representative by [CONTACT_756]. 
 Contacts for SAE reporting can be found in the Protocol.  
SAE reporting to the Sponsor’s representative  via paper CRF (if eCRF is not available) 
 Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to the Sponsor’s representative. 
 In rare circumstances and in the absence of facsimile equipm ent, notification by [CONTACT_13186] a copy of the SAE data co llection tool sent by [CONTACT_13187]. 
 Initial notification via telephone does not replace the need for th e Investigator to complete 
and sign the SAE CRF page s within the designated reporting time frames. 
 Contacts for SAE reporting can be found in the Protocol.  
Amended Clinical Trial Protocol [ADDRESS_248962]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 80 10.4 APPENDIX 4: CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY 
INFORMATION  
DEFINITIONS: 
Woman of childbearing potential (WOCBP) A woman is considered fertile following menarc he and until becoming post-menopausal unless 
permanently sterile (see below). Women in the following categories are not considered WOCBP 
1. Premenarchal. 
2. Premenopausal female with 1 of the following: 
- Documented hysterectomy. 
- Documented bilateral salpi[INVESTIGATOR_1656]. 
- Documented bilate ral oophorectomy. 
Note: Documentation can come from the site personnel’s: re view of the participant’s 
medical records, medical examination, or medical history interview. 
3. Postmenopausal female - A postmenopausal state is defined as no mens es for 12 months without an alternative 
medical cause. A high follicle stimulating hor mone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopa usal state in women not using hormonal 
contraception or hormonal replacement ther apy (HRT). However, in the absence of 
[ADDRESS_248963] atus before study enrollment.  
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception cons istently and correctly  as described in Table 14 . 
Table 14 - Highly effective contraceptive methods  
Highly effective contraceptive methods that are user dependenta 
Failure rate of <1% per year when used consistently and correctly.  
Combined (estrogen and progestogen containing) hormonal contra ception associated with inhibition of ovulation 
 Oral 
 Intravaginal 
 Transdermal 
Progestogen only hormonal contraception asso ciated with inhibition of ovulation 
 Oral 
 Injectable 
Amended Clinical Trial Protocol [ADDRESS_248964]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 81 Highly effective methods that are user independenta 
 Progestin only Implants 
 Intrauterine device (IUD) 
 Intrauterine hormone-releasing system (IUS) 
 Bilateral Tubal Ligation 
Vasectomized partner  
A vasectomized partner is a highly effective contraception method pr ovided that the partner is the sole male sexual partner of 
the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception 
should be used.  
Sexual abstinence  
Sexual abstinence is consi dered a highly effective method only if defined as refraining from heterosexual intercourse during th e 
entire period of risk associated with the study intervention. T he reliability of sexual abstinence needs to be evaluated in rel ation 
to the duration of the study and the preferred and usual lifestyle of the participant.  
NOTES:  
a Typi[INVESTIGATOR_35818]. Use should be consistent with local regul ations 
regarding the use of contraceptive methods for participants participating in clinical studies.  
PREGNANCY TESTING: 
 WOCBP should only be included after a confir med menstrual period and a negative highly 
sensitive serum pregnancy test (at Screening) . Urine pregnancy tests will be performed 
monthly subsequently. 
Additional pregnancy testing as shown in the SoA ( Section  1.3) and as follows. 
 Pregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected. 
COLLECTION OF PREGNAN CY INFORMATION: 
Female participants who become pregnant 
 The Investigator will collect  pregnancy information on a ny female participant who 
becomes pregnant while participating in this  study. Information will be recorded on the 
appropriate form and submitted to the Sponsor within 24 hours of learning of a 
participant's pregnancy. The part icipant will be followed to determine the outcome of the 
pregnancy. The Investigator wi ll collect follow-up information on the participant and the 
neonate and the information will be forwar ded to the Sponsor. Generally, follow-up will 
not be required for longer than 6 to 8 weeks beyond the estimated  delivery date. Any 
termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indica tion for the procedure. 
 Any pregnancy complication or elective termination of a pregnancy will be reported as an 
AE or SAE. A spontaneous abortion is alwa ys considered to be an SAE and will be 
reported as such. Any post-study pregnancy related SAE considered reasonably related to 
the study intervention by [CONTACT_208575]  8.3.5. While the Investigator is not obligated to actively seek this information in 
former study participants, he or she may learn of an SAE through spontaneous reporting. 
 Any female participant who becomes pregnant while part icipating in the study will 
discontinue study intervention. 
Amended Clinical Trial Protocol [ADDRESS_248965]-2023 
Version number: [ADDRESS_248966] pregnanc y information on any male participant’s female 
partner who becomes pregnant while  the male participant is in this study. This applies only to 
male participants who receive study treatment. 
After obtaining the necessary signed informed consen t from the pregnant fe male partner directly, 
the Investigator will record pregnancy informati on on the appropriate form  and submit it to the 
Sponsor within 24 hours of learning of the partner’s pregnancy. The female partner will also be 
followed to determine the outcome of the pregnancy. Information on the status of the mother and 
child will be forwarded to the Sponsor. Generally, the follow-up will be no longer than 6 to  
8 weeks following the estimated delivery date. A ny termination of the pregnancy will be reported 
regardless of fetal status (presence or absence of anomalies) or indicat ion for the procedure. 
10.5 APPENDIX 5: GENETICS  
The purpose of the pharmacogenomic an alyses is to identify genomic associations with clinical or 
biomarker response to drug, other COPD clinic al outcome measures and possible AEs. In 
addition, associations between genomic variants  and prognosis or progression of COPD as well 
as related allergic/atopic diseases  may also be studied. These data may be used or combined with 
data collected from other studies to identify and validate genomic mark ers related to the study 
drug or COPD and related diseases. Analyses may include sequence determination or  single nucleotide polymorphism studies of 
candidate genes and surrounding genomic region s. Other methods, including whole-exome 
sequencing, whole-genome sequencing, DNA co py number variation, and transcriptome 
sequencing (or other methods for quantitating RNA expression) ma y also be performed. The list 
of methods may be expanded to include novel methodology that may be developed during the 
course of this study or sample  storage period. Results  from the genomic analyses will not be 
reported in the CSR. 
Amended Clinical Trial Protocol [ADDRESS_248967]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 83 10.6 APPENDIX 6: LIVER AND OTHER SAFETY: SUGGESTED ACTIONS AND  
FOLLOW-UP ASSESSMENTS   
 
*If unable to retest in 72 hours, use original lab results to decide on further reporting/monitoring/discontinuation. 
Note: “Baseline” refers to ALT sampled at baseline visit; or if baseline value unavailable, to the latest ALT sampled before th e baseline visit. 
The algorithm does not apply to the instances of increase in ALT during screening. See Section  10.3 for guidance on safety reporting. 
Normalization is defined as ≤ULN or baseline value, if baseline value is >ULN. ALT > [ADDRESS_248968]
Monitor LFTs every 72 hoursALT ≤ [ADDRESS_248969] ALT > [ADDRESS_248970] &
Total Bilirubin > [ADDRESS_248971] 
Permanent Discontinuation of IMPALT > [ADDRESS_248972] 
In ANY CASE, FOLLOW the instructions listed in the box below: 
1. INFORM the Site Monitor who will forward the information to the Study Manager
2. INVESTIGATE specifically for malaise with or without loss of consciousness, dizziness, and/or 
hypotension and/or epi[INVESTIGATOR_208495] 72 hours; rule out muscular injury
3. PERFORM the following tests:
- LFTs: AST, ALT, alkaline phosphatase, total and conjugated bilirubin and prothrombin time / INR
- CPK, serum creatinine, complete blood count- Anti-HAV IgM, anti-HBc IgM, (HBV-DNA if clinically indicated), anti-HCV and HCV RNA, anti-
CMV IgM and anti-HEV IgM antibodies
- Depending on the clinical context, check for recent infection with EBV, herpes viruses, and toxoplasma- Hepatobiliary ultrasonography (or other imaging investigations if needed)
4. CONSIDER Auto-antibodies: antinuclear, anti-DNA, anti-smooth muscle, anti-LKM
5. CONSIDER consulting with hepatologist
6. CONSIDER patient hospi[INVESTIGATOR_155074]>2 (or PT<50%) and/or central nervous system disburbances 
suggesting hepatic encephalopathy
7. MONITOR LFTs after discontinuation of IMP:
-As closely as possible (or every 48 hours) until stabilization, then every 2 weeks until return to 
normal/baseline or clinical resolution.
8. FREEZE serum sample (5ml x 2)
9. In case of SUSPI[INVESTIGATOR_155075], a DNA diagnostic test should be doneCOMPLETE  the specific CRF forms 
for „ALT Increase”  and inform the 
Monitoring  Team within 24 hours
Confirm ALT > [ADDRESS_248973] within 72 hours of initial sample*
IMP administration can be continued as 
long as – under close monitoring –
conditions for permanent 
discontinuation or temporary 
interruption per protocol are not metINCREASE IN ALT
Amended Clinical Trial Protocol [ADDRESS_248974]-2023 
Version number: [ADDRESS_248975]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 85 10.7 APPENDIX 7: LIST OF PROHIBITED LIVE ATTENUATED VACCINES  
 Bacillus Calmette-Guérin (BCG) antituberculosis vaccine. 
 Chickenpox (Varicella). 
 Intranasal influenza (FluMist-Influenza); inac tive influenza vaccine delivered by [CONTACT_125497]. 
 Measles (Rubeola). 
 Measles-mumps-rubella (MMR) combination. 
 Measles-mumps-rubella-varicella (MMRV) combination. 
 Mumps. 
 Oral polio (Sabin). 
 Oral typhoid. 
 Rotavirus. 
 Rubella. 
 Smallpox (Vaccinia). 
 Varicella Zoster (shingles). 
 Yellow fever. 
This list is indicativ e and not exhaustive. 
10.8 APPENDIX 8: COUNTRY-SPECIFIC REQUIREMENTS  
Not applicable. 
10.9 APPENDIX 9: ABBREVIATIONS  
 
AC: Audit Committee AD: atopic dermatitis ADA: antidrug antibody AE: adverse event AECOPD: acute exacerbation of chr onic obstructive pulmonary disease 
AESI: adverse event of special interest ALT: alanine aminotransferase  ANA: anti-nuclear antibody AST: aspartate aminotransferase ATS: American Thoracic Society BCG: Bacillus Calmette-Guérin BD: bronchodilator 
BID: twice daily assessments 
BiPAP: bi ‐level positive airway pressure 
BMI: Body‑ Mass Index 
Amended Clinical Trial Protocol [ADDRESS_248976]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 86 BODE: Body-mass index, airflow Obstruction, Dyspnea, and Exercise 
CAT: COPD assessment test CFR: Code of Federal Regulations CI: confidence interval CIOMS: Council for International Or ganizations of Me dical Sciences 
CONSORT: Consolidated Standards of Reporting Trials COPD: chronic obstructive pulmonary disease CRF: Case Report Form 
CRSwNP: chronic rhinosinusi tis with nasal polyposis 
CSR: clinical study report 
CT: computed tomography 
CV: cardiovascular DMC: Data monitoring Committee DNA: deoxyribonucleic acid DPI: [INVESTIGATOR_208496]: Direct to Patient EC: European Commission 
ECG: electrocardiogram eCRF: electronic Case Report Form ELISA: enzyme-linked immunosorbent assay EOS: End of Study EOT: end of treatment EQ-5D-5L: Euro Quality of Life-5  Dimension 5-Level questionnaire 
E-RS: Evaluating Respi[INVESTIGATOR_208497]: early treatment discontinuation EU: European Union 
EudraCT: European Union Drug Regulat ing Authorities Clinical Trials 
EXACT: Exacerbations of Chronic Pulmonary Disease Tool FDA: US Food and Drug Administration FEF: forced expi[INVESTIGATOR_208498]: fractional exha led nitric oxide 
FEV1: forced expi[INVESTIGATOR_208499]: follicle stim ulating hormone 
FVC: forced vital capacity GCP: Good Clinical Practices GDPR: Global Data Protection Regulation GINA: Global Initiative for Asthma GSO: Global Safety Officer GWAS: genome-wide association study HBV: hepatitis B virus HCV: hepatitis C virus HFA: hydrofluoroalkane HIPAA: Health Insurance Port ability and Accountability Act 
HIV: Human Immunodeficiency Virus HLGT: high-level group term HLT: high level term 
Amended Clinical Trial Protocol [ADDRESS_248977]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 87 HRT: hormonal replacement therapy 
IB: Investigator’s Brochure ICF: informed consent form ICH: International Counc il for Harmonisation of T echnical Requirements for 
Pharmaceuticals for Human Use 
ICS: inhaled corticosteroid 
IEC: Independent Ethics Committee IgE: Immunoglobulin E 
IL-13: Interleukin 13 IL-4: interleukin 4 IL-4Rα: Interleukin-4 receptor alpha 
IL-5: Interleukin-5 IMP: investigational medicinal product INN: International Nonproprietary Names IRB: Institutional Review Board IRT: Interactive Response Technology ITT: intent-to-treat IUD: Intrauterine device IUS: Intrauterine hormone-releasing system IVIG: intravenous immunoglobulin IVRS: interactive voice response system IWRS: interactive we b response system 
LABA: long acting beta agonist LAMA: long acting muscarinic antagonist LS: least square 
mAbs: monoclonal antibodies MDI: metered dose inhaler MMR: Measles-mumps-rubella mMRC: Modified Medical Research Council Dyspnea Scale MMRM: mixed-effect model wi th repeated measures 
MMRV: Measles-mumps-rubella-varicella MRI: magnetic resonance imaging NIMP: noninvestigational medicinal product NYHA: [LOCATION_001] Heart Associat ion Functional Classification 
OCS: oral corticosteroids PARC: pulmonary and activa tion-regulated chemokine 
PCSA: potentially clinically  significant abnormality 
PMDA: Pharmaceuticals and Medical Devices Agency PT: preferred term 
SABA: short-acting β agonists 
SAP: statistical analysis plan SGRQ: St. George's Re spi[INVESTIGATOR_208500]: schedule of activities SOC: system organ class SOP: standard operating procedure S[LOCATION_003]R: suspected unexpected serious adverse reactions 
Amended Clinical Trial Protocol [ADDRESS_248978]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 88 TEAE: treatment emergent adverse event 
TIA: transient ischemic attack TNF: tumour necrosis factor ULN: upper limit of normal US: [LOCATION_002] VAS: Visual Analog Scale WBC: white blood cells WHO: World Health Organization 
WOCBP: woman of childbearing potential 
β-hCG: Human chorionic gonadotropin-beta 
 
Amended Clinical Trial Protocol [ADDRESS_248979]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 89 10.10 APPENDIX 10: ST. GEORGE’S RESPI[INVESTIGATOR_208501] [ADDRESS_248980]-2023 
Version number: [ADDRESS_248981]-2023 
Version number: [ADDRESS_248982]-2023 
Version number: [ADDRESS_248983]-2023 
Version number: [ADDRESS_248984]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 95 10.11 APPENDIX 11: THE EXACT AS FORMATTED FOR PERSONAL DIGITAL ASSISTANT 
(PDA)  

Amended Clinical Trial Protocol [ADDRESS_248985]-2023 
Version number: [ADDRESS_248986]-2023 
Version number: [ADDRESS_248987]-2023 
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 98 10.12 APPENDIX 12: EXACT QUESTIONNAIRE  

Amended Clinical Trial Protocol [ADDRESS_248988]-2023 
Version number: [ADDRESS_248989]-2023 
Version number: [ADDRESS_248990]-2023 
Version number: [ADDRESS_248991] rictly confidential Page 101 10.13 APPENDIX 13: BODE  

Amended Clinical Trial Protocol [ADDRESS_248992]-2023 
Version number: [ADDRESS_248993]-2023 
Version number: [ADDRESS_248994]-2023 
Version number: [ADDRESS_248995] rictly confidential Page 105 10.15 APPENDIX 15: DEFINITION OF ANAPHYLAXIS  
“Anaphylaxis is a serious allerg ic reaction that is rapid in  onset and may cause death ( 27)." 
Clinical criteria for diagnosing anaphylaxis  
 
10.16 APPENDIX 16: LIST OF OPPORTUNISTIC INFECTIONS  
 Aspergillosis. 
 Blastomyces dermatitidis (endemic in the sout h-eastern and south-centr al states US, along 
Mississippi [INVESTIGATOR_208502]). 
 Candidiasis - only systemic or extensiv e mucosal or cutane ous candidiasis.  
 Coccidioides immitis (endemic south-wester n US and Central and South America). 
 Cryptococcus. 
 Cytomegalovirus. 
 Herpes Simplex (disseminated). 
 Herpes Zoster (disseminated; ophthalmic; involvement of 2 or more dermatomes). 
 Histoplasmosis (pulmonary or disse minated; most common tropi[INVESTIGATOR_208503]-Ohio-Mississippi [INVESTIGATOR_208504]). 
 Listeriosis. 
 Mycobacterium tuberculosis. 
 Mycobacterium avium. 
 Nontuberculosis mycobacteria. 
 Pneumocystis pneumonia (PCP). 
This list is indicativ e and not exhaustive.  

Amended Clinical Trial Protocol [ADDRESS_248996]-2023 
Version number: [ADDRESS_248997] rictly confidential Page 106 10.17 APPENDIX 17: FUTURE USE OF SAMPLES  
Not all of the samples collected during this study may be required for the tests planned in this 
clinical trial. For patient(s) who have consented to  it, the samples that are archived, unused or left 
over after planned testing may be used for addi tional research purposes (any genetic analysis 
subject to additional consent per Section 8.7). For patients who have consented to it, archival 
blood samples will be collected at the visi ts specified in the study flow chart (see Section 1.3). 
Additional details will be provi ded in the laboratory manual. 
These archived serum and plasma samples, and any residual or leftover serum, plasma or blood 
remaining from planned laboratory work, may be used for research  purposes related to COPD or 
other respi[INVESTIGATOR_208505]  (eg, exploratory biomarkers of 
disease or drug effect), pathway biology, additional drug safety assessments or development and 
validation of bioassay methods beyond those define d in the present protocol. These samples will 
remain labelled with the same identifiers as the ones used during the study (ie, Subject ID, sample 
ID). They will be transferred to a [COMPANY_011] site (or a subcontractor site) which can be located outside 
of the country where the study is conducted. Th e Sponsor has included safeguards for protecting 
subject confidentiality  and personal data ( Section  10.1.3). 
10.18 APPENDIX 18: HIGH DOSE OF INHALED CORTICOSTEROIDS: ADULTS  
The following list of high dose of ICS is not a comp rehensive list; the ICS th at are not part of the 
list should be discussed with the Sponsor to confirm high vs. lower dose prior to randomization. 
Note: The reported ICS doses in the Ta bles below refer to METERED dose. 
 
Inhaled corticosteroid Daily dose (mcg) 
 High Lower doses 
Beclometasone dipropi[INVESTIGATOR_16847] (CFC) >1000 ≤1000 
Beclometasone dipropi[INVESTIGATOR_16847] (HFA) >400 ≤400 
Budesonide (DPI) >800 ≤800 
Ciclesonide (HFA) >320 ≤320 
Fluticasone propi[INVESTIGATOR_16847] (DPI [INVESTIGATOR_208444]) >500 ≤500 
Mometasone furoate  >440 ≤440 
Triamcinolone acetonide >2000 ≤2000 
(Adapted from GINA 2014 Guidance). 
High dose of inhaled corticos teroids:  Adults (Japan) 
 
Inhaled corticosteroid Daily dose (mcg) 
 High dose Lower doses 
Beclometasone dipropi[INVESTIGATOR_16847] (HFA) 401-800 ≤400 
Fluticasone propi[INVESTIGATOR_16847] (HFA) 401-800 ≤400 
Ciclesonide (HFA) 401-800 ≤400 
Fluticasone propi[INVESTIGATOR_16847] (DPI) 401-800 ≤[ADDRESS_248998]-2023 
Version number: [ADDRESS_248999] rictly confidential Page 107 Inhaled corticosteroid Daily dose (mcg) 
 High dose Lower doses 
Budesonide (DPI) 801-1600 ≤800 
Budesonide inhalation suspension  1<x<=2 ≤1.0 
(Adapted from Japanese Asthma Prevention and Management Guideline 2018).  
CFC - chlorofluorocarbon; HFA - hydrofluoroalkane; DPI - dry powder inhaler. 
10.19 APPENDIX 19: PROTOCOL AMENDMENT HISTORY  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Tabl e of Contents (TOC). 
10.19.1 Amended protocol 01 (Amendment 01) (29-September-2020)  
This amended protocol 01 (amendment  01) is considered to be subs tantial based on the criteria set 
forth in Article 10(a) of Direct ive 2001/20/EC of the European Parliament and the Council of the 
European Union. 
OVERALL RATIONALE FO R THE AMENDMENT 
The overall rationale for the cha nges implemented in the protocol amendment is to decrease the 
study burden on patients, to minimize COVID-19 pa ndemic-related risks in this vulnerable and 
elderly population of COPD patients, and to update  the AESIs with the updated Sponsor safety 
information related to eye disorders. 
Protocol amendment summary of changes table 
Section # and Name [CONTACT_208583] 
1.3.1 Schedule of 
activities for patients who complete the planned 
treatment 
And 
1.3.2 Reduced schedule 
of events for patients after early treatment 
discontinuation Replaced the following on-site visi ts with telephone visits:V7 (w16), 
V8 (w20), V10 (w28), V11 (W32), V13 (w40), V15 (w48), V17 (w56), V18 (w60). 
Footnotes added and updated to reflect this change. The 
assessments were adjusted accordingly. To decrease the burden 
of on-site visits for patients while maintaining patient safety and data 
quality; to minimize 
COVID-19 pandemic-related risks in vulnerable and elderly population of 
COPD patients. 
BODE score added at EOT/ETD  Omission corrected 
1.3.1 Schedule of 
activities for patients who complete the planned 
treatment Added EQ-5D-5L assessment at w24 and w52. To develop the economic 
model 
Clarifying in table and footnote ‘l’ that the urine pregnancy test can 
be performed monthly at home using ‘urine dipsticks’, in between 
on-site visits. Update 
Updated footnote ‘a’ to clarifiy in case of missed scheduled on-site visits. Update 
Updated footnote ‘m’ to explain in case of missed spi[INVESTIGATOR_208506]-site visits. Update 
Amended Clinical Trial Protocol [ADDRESS_249000]-2023 
Version number: [ADDRESS_249001] rictly confidential Page 108 Section # and Name [CONTACT_23688] 
1.3.[ADDRESS_249002](s) Updated text/footnote ‘f’ to reflect that after at least [ADDRESS_249003] the IMP. Dupi[INVESTIGATOR_208507].  
Added below text: 
If the patient is unable or unwilling to administer IMP at home, 
injections can be performed at the site; or arrangements can be made for qualified site personnel and/or health care professionals 
(eg, visiting nurse service) to administer IMP for the doses that are not scheduled to be given at the study site. Provided further clarity for administration of IMP 
1.3.[ADDRESS_249004] to be performed on w4, w8, w16, w20, 
w28, w32, w40, w44, and w48. Updated footnote ‘g’ to clarify  that 
the urine pregnancy test can be performed monthly at home using ‘urine dipsticks’, in between on-site visits.  
Update 
Removed pharmacokinetic assessments in case of ETD (early treatment discontinuation) at End of Study. Correction 
Whole blood RNA (optional) sampling added at ETD Correction 
EQ-5D-5L questionnaire added at ETD and updated footnote ‘i’. To develop the economic model. 
2.3 Benefit/Risk Assessment,  
[ADDRESS_249005] in Emergency situation like 
Covid-19 is added. To align with recent 
regulatory requests seeking to understand the Sponsor's risk mitigations during the 
COVID-19 pandemic. 
3 Objectives and 
Endpoints Updated a ‘tertiary/exploratory' endpoint wording from (“removed moderate to severe”): 
 Annualized rate of moderate to severe COPD exacerbations assessed by  [CONTACT_208576] 52 week. 
To: 
 Annualized rate of COPD exac erbations assessed by [CONTACT_208577] [ADDRESS_249006]. 
Updated the endpoints of “Other Secondary Objective” to reflect the 
deletion of pre-bronchodilator forced expi[INVESTIGATOR_208508] (FEV1) at w16, w20, w28 and w48; and deletion of forced 
expi[INVESTIGATOR_10229] (FEF) at w16, w28. Update based on deleted 
assessments for FEV1 and FEF because of 
replacement of on-site visits to telephone visits. 
5.1 Inclusion Criteria Updated I 02 to:  Participants with a physician diagnosis of COPD who meet the following criteria at screening. 
“at screening” was added. Clarity 
5.2 Exclusion Criteria E 33: removed “tuberculosis” from examples of invasive opportunistic 
infections. Clarity 
 E38: deleted the phrase “randomization (Visit 1)”. Revised text: 
Clinically significant labor atory tests at screening:… Correction 
Amended Clinical Trial Protocol [ADDRESS_249007]-2023 
Version number: [ADDRESS_249008] rictly confidential Page 109 Section # and Name [CONTACT_23688] 
5.4 Screen Failures Updated the bullet point for rescreening criteria from: 
 Fail to meet exclusion criteria. 
To: 
 Previously did not meet the criteria for participation in the 
study. To allow more flexibility 
for rescreening of 
patients. 
Moved the following sentence to another paragraph under same heading: 
If subject is rescreened, a different patient identification number will 
be issued. Clarity 
6.1.[ADDRESS_249009](s) Added below text: 
If the patient cannot take all the allocated IMP kits at home (eg. due 
to a storage issue), the DTP (Direc t to Patient) service can be used 
or the patient may come to the site to pi[INVESTIGATOR_9696]-up the IMP kits. For doses not given at the study site, diaries will be provided to record 
information related to the injections. The diary will be kept as source data in the patient’s study file. Provided further clarity for supply of IMP. 
6.2 Preparation/ Handling/ Storage/ Accountability 
- Responsibilities Added provision for local regulati on application for DTP (Direct to 
Patient) shipment. Clarity 
6.5 Concomitant Therapy Added reference to Section 6.1.2 for expected background therapy 
and allowed reliever medications. Clarity 
 The phrase " are allowed during the study " was removed from the 
sentence and updated as below (under permitted concomitant 
medications list): 
 Maintenance treatment of COPD with ICS, LABA, LAMA, 
at a stable dosage. Clarity 
7.1.[ADDRESS_249010] of criteria for permanent discontinuation of study 
intervention, replaced the phrase “in the study” by “on the study 
intervention” and updated the point as below: 
 If, in the Investigator's opi[INVESTIGATOR_1649], continuation on the study 
intervention would be detrimental to the patient's well-
being. 
Updated the below sentence from: 
''Patients must be withdrawn from the study for the following reasons:  
To: 
''Patients must be withdrawn from the study intervention for the 
following reasons:  Typographical correction 
 Moved the following point from temporary study intervention 
discontinuation to permanent discontinuation of study intervention: 
 If the patient misses more than [ADDRESS_249011]-2023 
Version number: [ADDRESS_249012] rictly confidential Page 110 Section # and Name [CONTACT_23688] 
8.3.[ADDRESS_249013] Added following AESIs: 
 Any severe type of conjunctivitis or blepharitis. 
 Keratitis. To align the AESIs with 
safety evaluation regarding eye related 
disorders with updated 
product information in IB 
edition 14. 
 Replaced the word “verbatim” by “overdose form” and updated the IMP overdose text as below: 
 An overdose (accidental or intentional) with the IMP is an 
event suspected by [CONTACT_208578] 11 days. The circumstances (ie, accidental or intentional) should be 
clearly specified in the ov erdose form and symptoms, if 
any, entered on separate adverse event forms. Clarity 
 Updated the NIMP overdose text to as below: 
 An overdose (accidental or intentional) with any NIMP is an 
event suspected by [CONTACT_208579] a drug label, within the 
intended therapeutic interval. The circumstances (ie, 
accidental or intentional) should be clearly specified in the overdose form and symptoms, if any, entered on separate 
adverse event forms. Clarity 
 Replaced below text: 
Of note, asymptomatic overdose has to be reported as a standard AE. 
by: 
[CONTACT_208580]. Clarity 
10.3 Appendix 3: Adverse 
Events: Definitions and Procedures for Recording, Evaluating, 
Follow-Up, and Reporting Updated the text in definition of SAE from: 
If an event is not an AE per definition above, then it cannot be an 
SAE even if serious conditions are met (eg, hospi[INVESTIGATOR_208509]/symptoms of the disease under study, death due to 
progression of disease). 
To: 
If an event is not an AE per definition above, then it cannot be an 
SAE. Clarity 
10.4 Appendix 4: 
Contraceptive Guidance and Collection of 
Pregnancy Information Added pregnancy data collection information for male participants with partners who become pregnant. To align with Sponsor 
standard operating 
procedure (SOP). 
Clarifying that the urine pregnancy test will be performed monthly instead of only on site visits. Update 
Throughout Correction of small errors (eg, comma errors, duplication of words); 
slight rewordings for clarity, removal of repeated footnote markers in SoA table, and updation of abbreviations. Correction 
Amended Clinical Trial Protocol [ADDRESS_249014]-2023 
Version number: [ADDRESS_249015] rictly confidential Page 111 10.19.2 Amended protocol 02 (Amendment 02) (16-December-2021)  
This amended protocol 02 (amendment  2) is considered to be subs tantial based on the criteria set 
forth in Article 10(a) of Direct ive 2001/20/EC of the European Parliament and the Council of the 
European Union. 
OVERALL RATIONALE FO R THE AMENDMENT 
The overall rationale for the ch anges implemented in the protoc ol amendment is to provide 
flexibility for participan t enrollment criteria while maintaini ng the favorable benefit risk profile 
and scientific objectives of the study. 
Protocol amendment summary of changes table 
Section # and Name [CONTACT_82417] 5.1 Inclusion 
Criteria Text in Inclusion Criterion I01: “participant must be ≥40 to ≤ 80 
years of age” was replaced with “participant must be ≥ 40 to ≤ 85 
years of age”. Upper age limit is increased to allow participation of older 
COPD patients who could potentially benefit from dupi[INVESTIGATOR_208510]-risk profile. 
Section 5.2 Exclusion 
Criteria Exclusion Criterion E02 wordings updated from: 
“A patient with current diagnosis of asthma or history of asthma 
according to the 2018 Global Initiative for Asthma (GINA) 
guidelines, or other accepted guidelines”  
To  “A patient with current diagnosis of asthma or history of asthma 
according to the Global Initiati ve for Asthma (GINA) guidelines, 
or other accepted guidelines”. For clarification. 
 Exclusion Criterion E05 revised from: 
“treatment with oxygen of more than 12 hours per day”  
To  
“Long-term treatment with oxygen >4.0 L/min OR if a participant 
requires more than 2.0 L/min in order to maintain oxygen saturation >88%”. To allow COPD patients on long-term oxygen therapy to 
participate in the study who 
could potentially benefit from dupi[INVESTIGATOR_208511]-risk profile. 
 Exclusion Criterion E17: updated wording by [CONTACT_1583] “eg,” within the sentence to clarify the exclusion criteria  For clarification.  
 Exclusion Criterion E18: Mov ed the following sentence to a new 
paragraph under the same exclusion criterion. 
“Prior history of malignancy or  active malignancy, including 
lymphoproliferative diseases (except successfully treated 
carcinoma in-situ of the cervix, non-metastatic squamous cell or 
basal cell carcinoma of the skin) within 5 years prior to baseline”. For clarification. 
Section 6.1 Study 
Intervention(s) Administered The term “consecutive visits” was replaced with “consecutive 
injections” in Table 2. For clarification. 
Amended Clinical Trial Protocol [ADDRESS_249016]-2023 
Version number: [ADDRESS_249017] rictly confidential Page 112 Section # and Name [CONTACT_82417] 8.[ADDRESS_249018] “symptomatic” was added at the beginning of the following sentence: ‘Symptomatic overdose is an AESI (defined in Section 8.3.1). No antidote is available for dupi[INVESTIGATOR_12458].’ For clarification. 
Section 10.18 Appendix 18 Added a note for the tables, “the reported ICS doses in the Tables below refer to METERED doses”. For clarification. 
Throughout Minor editorial and document form atting revisions are made. Correction. 
 
Amended Clinical Trial Protocol [ADDRESS_249019]-2023 
Version number: [ADDRESS_249020] rictly confidential Page 113 11 REFERENCES  
 
1. Global strategy for the diagnosis, manageme nt, and prevention of chronic obstructive 
pulmonary disease (2017 report). 
2. Anthonisen NR, Connett JE, Kiley JP, Altose MD , Bailey WC, Buist AS, et al.  Effects of 
smoking intervention and the use of an inhale d anticholinergic bronchodilator on the rate of 
decline of FEV1. The Lung Health Study.  JAMA. 1994;272(19):1497-505. 
3. Fahy JV. Type [ADDRESS_249021], absent in many. Nat Rev Immunol. 
2015;15(1):57-65. 
4. Dunican EM, Fahy JV. The Role of Type 2 Inflammation in the Pathogenesis of Asthma 
Exacerbations. Ann Am Thorac Soc. 2015;[ADDRESS_249022] 2:S144-9. 
5. Ghebre MA, Pang PH, Diver S, Desai D, Bafadhe l M, Haldar K, et al. Biological exacerbation 
clusters demonstrate asthma a nd chronic obstructive pulmonary di sease overlap with distinct 
mediator and microbiome profiles. J Allergy Clin Immunol. 2018;141(6):2027-36.e12. 
6. Bafadhel M, Saha S, Siva R, McCormick M, Monteiro W, Rugman P,  et al. Sputum IL-5 
concentration is associated with a sputum eosinophilia and attenuated by [CONTACT_208581]. Respir ation. 2009;78(3):256-62. 
7. Singh D, Kolsum U, Brightling CE, Locanto re N, Agusti A, Tal-Singer R. Eosinophilic 
inflammation in COPD: preval ence and clinical characte ristics. Eur Respir J. 
2014;44(6):1697-700. 
8. Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, et al . Blood eosinophil count 
thresholds and exacerbations in patients with ch ronic obstructive pulmonary  disease. J Allergy 
Clin Immunol. 2018;141(6):2037-47.e10. 
9. Woodruff PG, Boushey HA, Dolganov GM, Ba rker CS, Yang YH, Donnelly S, et al. 
Genome-wide profiling identifi es epi[INVESTIGATOR_208512]. Proc Natl Acad Sci U S A. 2007;104(40):[ZIP_CODE]-63. 
10. Adeloye D, Chua S, Lee C, Basquill C, Papana  A, Theodoratou E, et al. Global and regional 
estimates of COPD prevalence : systematic review and me ta-analysis. J Glob Health. 
2015;5(2):[ZIP_CODE]. 
11. Guarascio AJ, Ray SM, Finch CK, Self TH. Th e clinical and economic  burden of chronic 
obstructive pulmonary disease in  the [LOCATION_003]. Clinicoecon Outcomes Res. 2013;5(1):235-45. 
12. Brusselle GG, Bracke K, Lahousse L. Targeted therapy with inhaled co rticosteroids in COPD 
according to blood eosinophil counts. Lancet Respir Med. 2015;3(6):416-7. 
Amended Clinical Trial Protocol [ADDRESS_249023]-2023 
Version number: [ADDRESS_249024] rictly confidential Page 114 13. Aaron SD, Vandemheen KL, Fergusson D, Malt ais F, Bourbeau J, Goldstein R, et al. 
Tiotropi[INVESTIGATOR_96867], Salmete rol, or Fluticasone-Salmeterol for Treatment 
of Chronic Obstructive Pulmonary Dis ease. Ann Intern Med. 2007;146(8):545-55. 
14. Calverley PM, Rabe KF, Goehring UM, Kristia nsen S, Fabbrit LM, Martinez FH, et al. 
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical 
trials. Lancet. 2009;374(9691):685-94. 
15. Brusselle, G Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, et al. Blood eosinophil 
levels as a biomarker in COPD. Resp Med, 2018;138: 21-31. 
16. Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for 
Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017;377(17):1613-29. 
17. Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, et al. 
Benralizumab for chronic obstructive pulm onary disease and s putum eosinophilia: a 
randomized, double-blind, placebo-controlled, phase 2a study.  Lancet Respir Med. 
2014;2(11):891-901. 
18. Bafahdel M, McKenna S, Terry S, Mistry V, Reid  C, Haldar P, et al. Acute Exacerbations of 
Chronic Obstructive Pulmonary Disease. Iden tification of Biologic Clusters and Their 
Biomarkers. Am J Respir Crit Care Med 2011;184:662-71. 
19. Christenson SA, Steiling K, van den Berge M,  Hijazi K, Hiemsa PS, Postma DS, et al. 
Asthma-COPD Overlap. Clinical Relevance of Genomic Signatures of Type 2 Inflammation 
in Chronic Obstructive Pulmonary Disease.  Am J Respir Crit Care Med 2015;191:758-66. 
20. Bade G, Khan MA, Srivastava AK, Khare P, So laiappan KK, Guleria R, et al. Serum cytokine 
profiling and enrichment analysis reveal the involvement of immunological and inflammatory 
pathways in stable patients w ith chronic obstructive pulmonary disease. Int J Chron Obstruct 
Pulmon Dis 2014;9:759-73. 
21. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J COPD 2006;1:39-
47. 
22. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coat es A, et al. Standardization 
of spi[INVESTIGATOR_038]. Series ‘‘ATS/ERS  TASK FORCE: Standardization of Lung Function Testing"  
Edited by [CONTACT_181308] V, Crapo R, and Viegi G. Eur Resir J. 2005;26(2):319-38. 
23. Jones PW, Quirk FH, Baveystock CM. The St George's Respi[INVESTIGATOR_6015]. Respir 
Med. 1991 Sep;[ADDRESS_249025] B:25-31; discussion 33-7. 
24. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status 
for chronic airflow limitation. The St. George's  Respi[INVESTIGATOR_6015]. Am Rev Respir 
Dis. 1992;145(6):1321-7. 
Amended Clinical Trial Protocol [ADDRESS_249026]-2023 
Version number: [ADDRESS_249027] rictly confidential Page 115 25. Celli BR, Cote CG, Marin JM, Casanova C, M ontes de Oca M, Mendez RA, et al. The body-
mass index, airflow obstruction, dyspnea, and exer cise capacity index in chronic obstructive 
pulmonary disease. N Engl J Med. 2004;350(10):1005-12. 
26. Kim K, Demets DL. Design and analysis of gr oup sequential tests based on the type I error 
spending rate function. Bi ometrika;74(1):149-154. 
27. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Bock SA , Branum A, et al.  
Second symposium on the definition and mana gement of anaphylax is: Summary report—
Second National Institute of Allergy and Infe ctious Disease/Food Allergy and Anaphylaxis 
Network symposium. J Allergy Clin Immunol.  2006;117:391-7. 
 